<!DOCTYPE html PUBLIC "-//W3C//DTD XHTML 1.0 Transitional//EN" "http://www.w3.org/TR/xhtml1/DTD/xhtml1-transitional.dtd">
<!-- saved from url=(0052)http://www.ncbi.nlm.nih.gov/pmc/articles/PMC1884190/ -->
<html xmlns="http://www.w3.org/1999/xhtml" xml:lang="en" lang="en"><head><meta http-equiv="Content-Type" content="text/html; charset=UTF-8">
        <!-- AppResources meta begin -->
        <script type="text/javascript">var ncbi_startTime = new Date();</script>
        <!-- AppResources meta end -->
        
        <!-- TemplateResources meta begin -->
        <meta name="paf_template" content="">

        <!-- TemplateResources meta end -->
        
        <!-- Logger begin -->
        <meta name="ncbi_db" content="pmc"><meta name="ncbi_pdid" content="article"><meta name="ncbi_acc" content=""><meta name="ncbi_domain" content="brjclinpharm"><meta name="ncbi_report" content="record"><meta name="ncbi_type" content="fulltext"><meta name="ncbi_objectid" content=""><meta name="ncbi_pcid" content="/articles/PMC1884190/"><meta name="ncbi_app" content="pmc">
        <!-- Logger end -->
        
        <title>Lack of effect of ketoconazole on the pharmacokinetics of rosuvastatin in healthy subjects</title>
        
        <!-- AppResources external_resources begin -->
        <link rel="stylesheet" href="./PMC1884190_files/jig.min.css"><script type="text/javascript" src="./PMC1884190_files/jig.min.js"></script>

        <!-- AppResources external_resources end -->
        
        <!-- Page meta begin -->
        <meta name="robots" content="INDEX,NOFOLLOW,NOARCHIVE"><link rel="canonical" href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC1884190/"><link rel="schema.DC" href="http://purl.org/DC/elements/1.0/"><meta name="citation_journal_title" content="British Journal of Clinical Pharmacology"><meta name="citation_title" content="Lack of effect of ketoconazole on the pharmacokinetics of rosuvastatin in healthy subjects"><meta name="citation_authors" content="Kelvin J Cooper, Paul D Martin, Aaron L Dane, Mike J Warwick, Ali Raza, Dennis W Schneck"><meta name="citation_date" content="January 2003"><meta name="citation_issue" content="1"><meta name="citation_volume" content="55"><meta name="citation_firstpage" content="94"><meta name="citation_doi" content="10.1046/j.1365-2125.2003.01720.x"><meta name="citation_abstract_html_url" content="/pmc/articles/PMC1884190/?report=abstract"><meta name="citation_pmid" content="12534645"><meta name="DC.Title" content="Lack of effect of ketoconazole on the pharmacokinetics of rosuvastatin in healthy subjects"><meta name="DC.Type" content="Text"><meta name="DC.Publisher" content="Wiley-Blackwell"><meta name="DC.Contributor" content="Kelvin J Cooper"><meta name="DC.Contributor" content="Paul D Martin"><meta name="DC.Contributor" content="Aaron L Dane"><meta name="DC.Contributor" content="Mike J Warwick"><meta name="DC.Contributor" content="Ali Raza"><meta name="DC.Contributor" content="Dennis W Schneck"><meta name="DC.Date" content="2003 Jan"><meta name="DC.Identifier" content="10.1046/j.1365-2125.2003.01720.x"><meta name="DC.Language" content="en"><meta property="og:title" content="Lack of effect of ketoconazole on the pharmacokinetics of rosuvastatin in healthy subjects"><meta property="og:type" content="article"><meta property="og:description" content="To examine in vivo the effect of ketoconazole on the pharmacokinetics of rosuvastatin, a 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase inhibitor.This was a randomized, double-blind, two-way crossover, placebo-controlled trial. Healthy male ..."><meta property="og:url" content="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC1884190/"><meta property="og:site_name" content="PubMed Central (PMC)"><meta property="og:image" content="http://www.ncbi.nlm.nih.gov/corehtml/pmc/pmcgifs/pmc-logo-share.png"><meta name="twitter:card" content="summary"><meta name="twitter:site" content="@ncbi"><link rel="stylesheet" href="./PMC1884190_files/pmc.min.css" type="text/css"><link rel="stylesheet" href="./PMC1884190_files/pmc_extras_prnt.min.css" type="text/css" media="print"><script type="text/javascript" src="./PMC1884190_files/common.min.js">//</script><script type="text/javascript" src="./PMC1884190_files/NcbiTagServer.min.js">//</script><meta name="citationexporter" content="backend:&#39;/pmc/utils/ctxp/&#39;"><script type="text/javascript" src="./PMC1884190_files/jquery.citationexporter.js">//</script><link rel="stylesheet" href="./PMC1884190_files/citationexporter.css" type="text/css"><script type="text/javascript" src="./PMC1884190_files/MathJax.js"></script><script type="text/javascript" src="./PMC1884190_files/large-obj-scrollbars.min.js"></script><script type="text/javascript">window.name="mainwindow";</script><style type="text/css">.pmc-wm {background:transparent repeat-y top left;background-image:url(/corehtml/pmc/pmcgifs/wm-brjclinpharm.gif);background-size: auto, contain}</style><style type="text/css">.print-view{display:block}</style><style type="text/css">
        div.pmc_para_cit li.highlight,
        div.pmc_para_cit li.highlight .one_line_source
        { background: #E0E0E0; }
        a.bibr.highlight { background: #E0E0E0; } 
      </style><link rel="alternate" type="application/epub+zip" href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC1884190/epub/"><link rel="alternate" type="application/pdf" href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC1884190/pdf/bcp0055-0094.pdf">

        <!-- Page meta end -->
    <link rel="shortcut icon" href="http://www.ncbi.nlm.nih.gov/favicon.ico"><meta name="ncbi_phid" content="8A1A639076C261110000000000907D5A"><link type="text/css" rel="stylesheet" href="./PMC1884190_files/3855312.css"><link type="text/css" rel="stylesheet" href="./PMC1884190_files/3929378.css" media="print"><style type="text/css" media="print">.print-log { position:absolute;left:-10000px;top:auto;width:1px;height:1px;overflow:hidden; }.print-log li { list-style-image: url('http://www.ncbi.nlm.nih.gov/stat?jsevent=print&ncbi_app=pmc&ncbi_db=pmc&ncbi_pcid=%2Farticles%2FPMC1884190%2F&ncbi_pdid=article&ncbi_phid=8A1A639076C261110000000000907D5A'); }</style><style type="text/css">.print-log { position:absolute;left:-10000px;top:auto;width:1px;height:1px;overflow:hidden; }</style><style type="text/css">.MathJax_Preview {color: #888}
#MathJax_Message {position: fixed; left: 1em; bottom: 1.5em; background-color: #E6E6E6; border: 1px solid #959595; margin: 0px; padding: 2px 8px; z-index: 102; color: black; font-size: 80%; width: auto; white-space: nowrap}
#MathJax_MSIE_Frame {position: absolute; top: 0; left: 0; width: 0px; z-index: 101; border: 0px; margin: 0px; padding: 0px}
.MathJax_Error {color: #CC0000; font-style: italic}
</style><style type="text/css">.MathJax_Hover_Frame {border-radius: .25em; -webkit-border-radius: .25em; -moz-border-radius: .25em; -khtml-border-radius: .25em; box-shadow: 0px 0px 15px #83A; -webkit-box-shadow: 0px 0px 15px #83A; -moz-box-shadow: 0px 0px 15px #83A; -khtml-box-shadow: 0px 0px 15px #83A; border: 1px solid #A6D ! important; display: inline-block; position: absolute}
.MathJax_Menu_Button .MathJax_Hover_Arrow {position: absolute; cursor: pointer; display: inline-block; border: 2px solid #AAA; border-radius: 4px; -webkit-border-radius: 4px; -moz-border-radius: 4px; -khtml-border-radius: 4px; font-family: 'Courier New',Courier; font-size: 9px; color: #F0F0F0}
.MathJax_Menu_Button .MathJax_Hover_Arrow span {display: block; background-color: #AAA; border: 1px solid; border-radius: 3px; line-height: 0; padding: 4px}
.MathJax_Hover_Arrow:hover {color: white!important; border: 2px solid #CCC!important}
.MathJax_Hover_Arrow:hover span {background-color: #CCC!important}
</style><style type="text/css">#MathJax_Zoom {position: absolute; background-color: #F0F0F0; overflow: auto; display: block; z-index: 301; padding: .5em; border: 1px solid black; margin: 0; font-weight: normal; font-style: normal; text-align: left; text-indent: 0; text-transform: none; line-height: normal; letter-spacing: normal; word-spacing: normal; word-wrap: normal; white-space: nowrap; float: none; -webkit-box-sizing: content-box; -moz-box-sizing: content-box; box-sizing: content-box; box-shadow: 5px 5px 15px #AAAAAA; -webkit-box-shadow: 5px 5px 15px #AAAAAA; -moz-box-shadow: 5px 5px 15px #AAAAAA; -khtml-box-shadow: 5px 5px 15px #AAAAAA; filter: progid:DXImageTransform.Microsoft.dropshadow(OffX=2, OffY=2, Color='gray', Positive='true')}
#MathJax_ZoomOverlay {position: absolute; left: 0; top: 0; z-index: 300; display: inline-block; width: 100%; height: 100%; border: 0; padding: 0; margin: 0; background-color: white; opacity: 0; filter: alpha(opacity=0)}
#MathJax_ZoomFrame {position: relative; display: inline-block; height: 0; width: 0}
#MathJax_ZoomEventTrap {position: absolute; left: 0; top: 0; z-index: 302; display: inline-block; border: 0; padding: 0; margin: 0; background-color: white; opacity: 0; filter: alpha(opacity=0)}
</style><style type="text/css">#MathJax_About {position: fixed; left: 50%; width: auto; text-align: center; border: 3px outset; padding: 1em 2em; background-color: #DDDDDD; color: black; cursor: default; font-family: message-box; font-size: 120%; font-style: normal; text-indent: 0; text-transform: none; line-height: normal; letter-spacing: normal; word-spacing: normal; word-wrap: normal; white-space: nowrap; float: none; z-index: 201; border-radius: 15px; -webkit-border-radius: 15px; -moz-border-radius: 15px; -khtml-border-radius: 15px; box-shadow: 0px 10px 20px #808080; -webkit-box-shadow: 0px 10px 20px #808080; -moz-box-shadow: 0px 10px 20px #808080; -khtml-box-shadow: 0px 10px 20px #808080; filter: progid:DXImageTransform.Microsoft.dropshadow(OffX=2, OffY=2, Color='gray', Positive='true')}
#MathJax_About.MathJax_MousePost {outline: none}
.MathJax_Menu {position: absolute; background-color: white; color: black; width: auto; padding: 5px 0px; border: 1px solid #CCCCCC; margin: 0; cursor: default; font: menu; text-align: left; text-indent: 0; text-transform: none; line-height: normal; letter-spacing: normal; word-spacing: normal; word-wrap: normal; white-space: nowrap; float: none; z-index: 201; border-radius: 5px; -webkit-border-radius: 5px; -moz-border-radius: 5px; -khtml-border-radius: 5px; box-shadow: 0px 10px 20px #808080; -webkit-box-shadow: 0px 10px 20px #808080; -moz-box-shadow: 0px 10px 20px #808080; -khtml-box-shadow: 0px 10px 20px #808080; filter: progid:DXImageTransform.Microsoft.dropshadow(OffX=2, OffY=2, Color='gray', Positive='true')}
.MathJax_MenuItem {padding: 1px 2em; background: transparent}
.MathJax_MenuArrow {position: absolute; right: .5em; padding-top: .25em; color: #666666; font-size: .75em}
.MathJax_MenuActive .MathJax_MenuArrow {color: white}
.MathJax_MenuArrow.RTL {left: .5em; right: auto}
.MathJax_MenuCheck {position: absolute; left: .7em}
.MathJax_MenuCheck.RTL {right: .7em; left: auto}
.MathJax_MenuRadioCheck {position: absolute; left: .7em}
.MathJax_MenuRadioCheck.RTL {right: .7em; left: auto}
.MathJax_MenuLabel {padding: 1px 2em 3px 1.33em; font-style: italic}
.MathJax_MenuRule {border-top: 1px solid #DDDDDD; margin: 4px 3px}
.MathJax_MenuDisabled {color: GrayText}
.MathJax_MenuActive {background-color: #606872; color: white}
.MathJax_MenuDisabled:focus, .MathJax_MenuLabel:focus {background-color: #E8E8E8}
.MathJax_ContextMenu:focus {outline: none}
.MathJax_ContextMenu .MathJax_MenuItem:focus {outline: none}
#MathJax_AboutClose {top: .2em; right: .2em}
.MathJax_Menu .MathJax_MenuClose {top: -10px; left: -10px}
.MathJax_MenuClose {position: absolute; cursor: pointer; display: inline-block; border: 2px solid #AAA; border-radius: 18px; -webkit-border-radius: 18px; -moz-border-radius: 18px; -khtml-border-radius: 18px; font-family: 'Courier New',Courier; font-size: 24px; color: #F0F0F0}
.MathJax_MenuClose span {display: block; background-color: #AAA; border: 1.5px solid; border-radius: 18px; -webkit-border-radius: 18px; -moz-border-radius: 18px; -khtml-border-radius: 18px; line-height: 0; padding: 8px 0 6px}
.MathJax_MenuClose:hover {color: white!important; border: 2px solid #CCC!important}
.MathJax_MenuClose:hover span {background-color: #CCC!important}
.MathJax_MenuClose:hover:focus {outline: none}
</style></head>
    <body class="article" id="ui-jig-5"><div id="MathJax_Message" style="display: none;"></div>
        <div class="grid">
            <div class="col twelve_col nomargin shadow">
                <!-- System messages like service outage or JS required; this is handled by the TemplateResources portlet -->
                <div class="sysmessages">
                    <noscript>
	&lt;p class="nojs"&gt;
	&lt;strong&gt;Warning:&lt;/strong&gt;
	The NCBI web site requires JavaScript to function. 
	&lt;a href="/guide/browsers/#enablejs" title="Learn how to enable JavaScript" target="_blank"&gt;more...&lt;/a&gt;
	&lt;/p&gt;
	</noscript>
                </div>
                <!--/.sysmessage-->
                <div class="wrap">
                    <div class="page">
                        <div class="top">
                            <div class="universal_header" id="universal_header"><ul class="inline_list jig-ncbimenu ui-ncbimenu resources_list ui-ncbibasicmenu orientation_hort" id="navcontent" role="menubar"><li class="ui-ncbimenu-item-leaf ui-ncbimenu-item-first ui-helper-reset ui-ncbimenu-item-no-hlt" role="presentation"><a class="ui-ncbimenu-link-first" href="http://www.ncbi.nlm.nih.gov/" role="menuitem" title="NCBI Home" id="ncbihome" accesskey="1"><span class="offscreen_noflow">NCBI</span><img src="./PMC1884190_files/28977" class="ncbi_logo" title="NCBI" alt="NCBI Logo"></a></li><li class="offscreen_noflow ui-ncbimenu-item-skip access"><a href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC1884190/#maincontent" title="Skip to the content" tabindex="0" accesskey="3">Skip to main
                        content</a></li><li class="offscreen_noflow ui-ncbimenu-item-skip access"><a href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC1884190/#navcontent" title="Skip to the navigation" tabindex="0" accesskey="4">Skip to
                        navigation</a></li><li id="resource-menu" class="topmenu ui-helper-reset ui-ncbimenu-item-first ui-helper-reset" role="presentation"><a class="ui-ncbimenu-first-link-has-submenu ui-ncbimenu-link-first topanchor expandDown" href="http://www.ncbi.nlm.nih.gov/static/header_footer_ajax/submenu/#resources" tabindex="-1" role="menuitem">Resources</a></li><li id="all-howtos-menu" class="topmenu ui-helper-reset ui-ncbimenu-item-first" role="presentation"><a class="ui-ncbimenu-first-link-has-submenu ui-ncbimenu-link-first topanchor expandDown" href="http://www.ncbi.nlm.nih.gov/static/header_footer_ajax/submenu/#howto" tabindex="-1" role="menuitem">How To</a></li><li class="offscreen_noflow ui-ncbimenu-item-skip access"><a href="http://www.ncbi.nlm.nih.gov/guide/browsers/#accesskeys" title="About My NCBI Accesskeys" tabindex="0" accesskey="0">About NCBI Accesskeys</a></li></ul><div class="myncbi"><span id="myncbiusername" style="display:none"><a href="http://www.ncbi.nlm.nih.gov/account/settings/" id="mnu" title="Edit account settings"></a></span><a accesskey="2" href="http://www.ncbi.nlm.nih.gov/myncbi/" id="myncbi" style="display:none">My NCBI</a><a href="http://www.ncbi.nlm.nih.gov/account/?back_url=http%3A%2F%2Fwww.ncbi.nlm.nih.gov%2Fpmc%2Farticles%2FPMC1884190%2F" id="sign_in">Sign in to NCBI</a><a href="http://www.ncbi.nlm.nih.gov/account/signout/?back_url=http%3A%2F%2Fwww.ncbi.nlm.nih.gov%2Fpmc%2Farticles%2FPMC1884190%2F" id="sign_out" style="display:none">Sign Out</a></div></div>
                            <div class="header">
    <div class="res_logo">
  <h1 class="img_logo"><a href="http://www.ncbi.nlm.nih.gov/pmc/" class="pmc_logo offscreen">PMC</a></h1>
  <div class="NLMLogo">
    <a href="http://www.nlm.nih.gov/" title="US National Library of Medicine">US National Library of Medicine</a>
    <br>
    <a href="http://www.nih.gov/" title="National Institutes of Health">National Institutes of Health</a>
  </div>
</div>
    <div class="search"><form method="get" action="http://www.ncbi.nlm.nih.gov/pmc/"><div class="search_form"><label for="database" class="offscreen_noflow">Search database</label><select id="database"><optgroup label="Recent"><option value="pmc" selected="selected" data-ac_dict="pmc-search-autocomplete">PMC</option><option value="pubmed" class="last">PubMed</option></optgroup><optgroup label="All"><option value="gquery">All Databases</option><option value="assembly">Assembly</option><option value="bioproject">BioProject</option><option value="biosample">BioSample</option><option value="biosystems">BioSystems</option><option value="books">Books</option><option value="clinvar">ClinVar</option><option value="clone">Clone</option><option value="cdd">Conserved Domains</option><option value="gap">dbGaP</option><option value="dbvar">dbVar</option><option value="nucest">EST</option><option value="gene">Gene</option><option value="genome">Genome</option><option value="gds">GEO DataSets</option><option value="geoprofiles">GEO Profiles</option><option value="nucgss">GSS</option><option value="gtr">GTR</option><option value="homologene">HomoloGene</option><option value="medgen">MedGen</option><option value="mesh">MeSH</option><option value="ncbisearch">NCBI Web Site</option><option value="nlmcatalog">NLM Catalog</option><option value="nuccore">Nucleotide</option><option value="omim">OMIM</option><option value="pmc" data-ac_dict="pmc-search-autocomplete">PMC</option><option value="popset">PopSet</option><option value="probe">Probe</option><option value="protein">Protein</option><option value="proteinclusters">Protein Clusters</option><option value="pcassay">PubChem BioAssay</option><option value="pccompound">PubChem Compound</option><option value="pcsubstance">PubChem Substance</option><option value="pubmed">PubMed</option><option value="pubmedhealth">PubMed Health</option><option value="snp">SNP</option><option value="sra">SRA</option><option value="structure">Structure</option><option value="taxonomy">Taxonomy</option><option value="toolkit">ToolKit</option><option value="toolkitall">ToolKitAll</option><option value="toolkitbook">ToolKitBook</option><option value="toolkitbookgh">ToolKitBookgh</option><option value="unigene">UniGene</option></optgroup></select><div class="nowrap"><label for="term" class="offscreen_noflow" accesskey="/">Search term</label><div class="nowrap"><div class="ui-ncbiclearbutton-wrap box-shadow"><input type="text" name="term" id="term" title="Search PMC. Use up and down arrows to choose an item from the autocomplete." value="" class="jig-ncbiclearbutton jig-ncbiautocomplete" config="dictionary:&#39;pmc-search-autocomplete&#39;,disableUrl:&#39;NcbiSearchBarAutoComplCtrl&#39;" autocomplete="off" data-sbconfig="ds:&#39;no&#39;,pjs:&#39;no&#39;,afs:&#39;yes&#39;" aria-haspopup="true" aria-autocomplete="list" role="textbox"><a class="reset" href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC1884190/#" style="visibility: hidden;"><img src="./PMC1884190_files/clear.png" alt="Clear input"></a></div></div><button id="search" type="submit" class="button_search nowrap" cmd="go">Search</button></div></div></form><ul class="searchlinks inline_list"><li>
                        <a href="http://www.ncbi.nlm.nih.gov/pmc/limits/">Limits</a>
                    </li><li>
                        <a href="http://www.ncbi.nlm.nih.gov/pmc/advanced/">Advanced</a>
                    </li><li>
                        <a href="http://www.ncbi.nlm.nih.gov/pmc/journals/">Journal list</a>
                    </li><li class="help">
                        <a target="_blank" href="http://www.ncbi.nlm.nih.gov/books/NBK3825/">Help</a>
                    </li></ul></div>
</div>

                            
                            
                        <!--<component id="Page" label="headcontent"/>-->
                            
                        </div>
                        <div class="content">
                            <!-- site messages -->
                            <div class="container">
    <div id="maincontent" class="content eight_col col">
        <div class="navlink-box">
            <ul class="page-breadcrumbs inline_list small"><li class="journal-list"><a href="http://www.ncbi.nlm.nih.gov/pmc/journals/" class="navlink">Journal List</a></li><li class="archive-page"><a class="navlink" href="http://www.ncbi.nlm.nih.gov/pmc/journals/279/">Br J Clin Pharmacol</a></li><li class="issue-page"><a class="navlink" href="http://www.ncbi.nlm.nih.gov/pmc/issues/144659/">v.55(1); 2003 Jan</a></li><li class="accid">PMC1884190</li></ul>
        </div>

        <!-- Journal banner -->
        <div class="pmc-page-banner whole_rhythm"><div><img src="./PMC1884190_files/logo-brjclinpharm.gif" alt="Logo of brjclinpharm" usemap="#logo-imagemap"><map id="logo-imagemap" name="logo-imagemap"><area alt="Link to Publisher&#39;s site" title="Link to Publisher&#39;s site" shape="default" coords="0,0,499,74" href="http://www.blackwellpublishing.com/journal.asp?ref=0306-5251" target="pmc_ext" ref="reftype=publisher&amp;article-id=1884190&amp;issue-id=144659&amp;journal-id=279&amp;FROM=Article%7CBanner&amp;TO=Publisher%7COther%7CN/A&amp;rendering-type=normal"></map></div> </div>
        
        <!--component id='MainPortlet' label='search-reference'/-->
        
        <!-- Book content -->
        <div class="">
            
        
            
            <div class="hide-overflow article lit-style content pmc-wm slang-all page-box"><!--main-content--><div class="jig-ncbiinpagenav" data-jigconfig="smoothScroll: false, allHeadingLevels: [&#39;h2&#39;], headingExclude: &#39;:hidden&#39;" id="ui-jig-1"><div class="fm-sec half_rhythm no_top_margin"><div class="fm-citation half_rhythm no_top_margin clearfix"><div class="small"><div class="inline_block eight_col va_top"><div><div><span class="cit">Br J Clin Pharmacol. 2003 Jan; 55(1): 94–99. </span></div><div>  <span class="doi">doi:&nbsp; <a href="http://dx.doi.org/10.1046%2Fj.1365-2125.2003.01720.x" target="pmc_ext" ref="reftype=other&amp;article-id=1884190&amp;issue-id=144659&amp;journal-id=279&amp;FROM=Article%7CFront%20Matter&amp;TO=Content%20Provider%7CCrosslink%7CDOI&amp;rendering-type=normal">10.1046/j.1365-2125.2003.01720.x</a></span></div></div></div><div class="inline_block four_col va_top show-overflow align_right"><div class="fm-citation-ids"><div class="fm-citation-pmcid"><span class="fm-citation-ids-label">PMCID: </span><span>PMC1884190</span></div></div></div></div></div><h1 class="content-title">Lack of effect of ketoconazole on the pharmacokinetics of rosuvastatin in healthy subjects</h1><div class="half_rhythm"><div class="contrib-group fm-author"><a href="http://www.ncbi.nlm.nih.gov/pubmed/?term=Cooper%20KJ%5Bauth%5D">Kelvin J Cooper</a>, <a href="http://www.ncbi.nlm.nih.gov/pubmed/?term=Martin%20PD%5Bauth%5D">Paul D Martin</a>, <a href="http://www.ncbi.nlm.nih.gov/pubmed/?term=Dane%20AL%5Bauth%5D">Aaron L Dane</a>, <a href="http://www.ncbi.nlm.nih.gov/pubmed/?term=Warwick%20MJ%5Bauth%5D">Mike J Warwick</a>, <a href="http://www.ncbi.nlm.nih.gov/pubmed/?term=Raza%20A%5Bauth%5D">Ali Raza</a>,<sup>1</sup> and  <a href="http://www.ncbi.nlm.nih.gov/pubmed/?term=Schneck%20DW%5Bauth%5D">Dennis W Schneck</a><sup>2</sup></div></div><div class="fm-panel small half_rhythm"><div class="fm-authors-info fm-panel hide half_rhythm" id="id203434_ai" style="display:none"><div class="fm-affl" lang="en">AstraZeneca, Alderley Park, Macclesfield, UK</div><div class="fm-affl" lang="en"><sup>1</sup>AstraZeneca, Wayne, Philadelphia, USA</div><div class="fm-affl" lang="en"><sup>2</sup>AstraZeneca, Wilmington, Delaware, USA</div><div id="cor1">Correspondence: Paul D. Martin, AstraZeneca, Mereside, Alderley Park, Macclesfield, Cheshire SK10 4TG, UK. Tel.: + 44 0 1625 518171; Fax: + 44 0 1625 516962; E-mail: <a href="mailto:dev@null" data-email="moc.acenezartsa@nitram.luap" class="oemail">moc.acenezartsa@nitram.luap</a></div></div><div class="togglers"><a href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC1884190/#" class="pmctoggle" rid="id203434_ai">Author information <span>►</span></a> <a href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC1884190/#" class="pmctoggle" rid="id203434_an">Article notes <span>►</span></a> <a href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC1884190/#" class="pmctoggle" rid="id203434_cpl">Copyright and License information <span>►</span></a></div><div class="fm-article-notes fm-panel hide half_rhythm" id="id203434_an" style="display:none"><div class="fm-pubdate half_rhythm">Received 2002 Mar 25; Accepted 2002 Jun 13.</div></div><div class="fm-cpl-info fm-panel hide half_rhythm" id="id203434_cpl" style="display:none"><div class="fm-copyright half_rhythm"><a href="http://www.ncbi.nlm.nih.gov/pmc/about/copyright.html">Copyright</a> © 2003 Blackwell Science Ltd</div></div></div><div class="links-box fm-panel whole_rhythm"><div class="small"><div>This article has been <a href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC1884190/citedby/">cited by</a> other articles in PMC.</div></div></div></div><div class="sec"></div><div id="__abstractid163722" lang="en" class="tsec sec"><div class="goto jig-ncbiinpagenav-goto-container" id="ui-jig-7"><span role="menubar"><a class="tgt_dark page-toc-label jig-ncbiinpagenav-goto-heading" href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC1884190/#" title="Go to other sections in this page" role="menuitem" aria-expanded="false" aria-haspopup="true" id="ui-jig-8">Go to:</a></span></div><h2 class="head no_bottom_margin ui-helper-clearfix" id="__abstractid163722title">Abstract</h2><!--article-meta--><div><div id="__sec1" class="sec sec-first"><h3>Aims</h3><p id="__p1" class="p p-first-last">To examine <em>in vivo</em> the effect of ketoconazole on the pharmacokinetics of rosuvastatin, a 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase inhibitor.</p></div><div id="__sec2" class="sec"><h3>Methods</h3><p id="__p2" class="p p-first-last">This was a randomized, double-blind, two-way crossover, placebo-controlled trial. Healthy male volunteers (<em>n</em> = 14) received ketoconazole 200 mg or placebo twice daily for 7 days, and rosuvastatin 80 mg was coadministered on day 4 of dosing. Plasma concentrations of rosuvastatin, and active and total HMG-CoA reductase inhibitors were measured up to 96 h postdose.</p></div><div id="__sec3" class="sec"><h3>Results</h3><p id="__p3" class="p p-first-last">Following coadministration with ketoconazole, rosuvastatin geometric least square mean AUC(0,<em>t</em>) and <em>C</em><sub>max</sub> were unchanged compared with placebo (treatment ratios (90% confidence intervals): 1.016 (0.839, 1.230), 0.954 (0.722, 1.260), respectively). Rosuvastatin accounted for essentially all of the circulating active HMG-CoA reductase inhibitors and most (&gt; 85%) of the total inhibitors. Ketoconazole did not affect the proportion of circulating active or total inhibitors accounted for by circulating rosuvastatin.</p></div><div id="__sec4" class="sec sec-last"><h3>Conclusions</h3><p id="__p4" class="p p-first-last">Ketoconazole did not produce any change in rosuvastatin pharmacokinetics in healthy subjects. The data suggest that neither cytochrome P450 3A4 nor P-gp-mediated transport contributes to the elimination of rosuvastatin.</p></div></div><div class="sec"><strong class="kwd-title">Keywords: </strong><span class="kwd-text">CYP3A4, ketoconazole, P-glycoprotein, rosuvastatin</span></div></div><div id="__sec5" class="tsec sec"><div class="goto jig-ncbiinpagenav-goto-container" id="ui-jig-9"><a class="tgt_dark page-toc-label jig-ncbiinpagenav-goto-heading" href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC1884190/#" title="Go to other sections in this page" role="button" aria-expanded="false" aria-haspopup="true" id="ui-jig-10">Go to:</a></div><h2 class="head no_bottom_margin ui-helper-clearfix" id="__sec5title">Introduction</h2><p id="__p5" class="p p-first">Rosuvastatin (Crestor®) is an inhibitor of 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase, the rate-limiting enzyme in cholesterol biosynthesis, and is effective for the treatment of patients with dyslipidaemia. In clinical trials, rosuvastatin (1-80 mg) produced highly significant dose-dependent reductions in low-density lipoprotein cholesterol (up to 65%) and was well-tolerated [<a href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC1884190/#b1" rid="b1" class=" bibr popnode tag_hotlink tag_tooltip" id="__tag_130180316" role="button" aria-expanded="false" aria-haspopup="true">1</a>].</p><p id="__p6">The pharmacokinetics of rosuvastatin following single- and multiple-dose administration of the drug to healthy volunteers have been investigated in several trials ([<a href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC1884190/#b2" rid="b2" class=" bibr popnode tag_hotlink tag_tooltip" id="__tag_384404582" role="button" aria-expanded="false" aria-haspopup="true">2</a>] and AstraZeneca data on file [manuscript in preparation]). The absolute oral bioavailability was estimated as 20.1%, which, together with an estimated hepatic extraction ratio of 0.63, implies that absorption was greater than 20%. Systemic exposure was dose proportional over the dose range 10–80 mg, and the elimination half-life was about 20 h.</p><p id="__p7">Elimination of rosuvastatin is primarily via the liver. In a clinical trial [<a href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC1884190/#b3" rid="b3" class=" bibr popnode" role="button" aria-expanded="false" aria-haspopup="true">3</a>], 90% of an orally administered dose of <sup>14</sup>C-radiolabelled rosuvastatin was recovered in faeces as unchanged drug, a result consistent with metabolism being a minor route of clearance. <em>In vitro</em> studies with human hepatic microsomes and hepatocytes demonstrated only limited metabolism of rosuvastatin [<a href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC1884190/#b4" rid="b4" class=" bibr popnode" role="button" aria-expanded="false" aria-haspopup="true">4</a>], and cytochrome P450 2C9 (CYP2C9) appeared to be the principal enzyme involved [<a href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC1884190/#b4" rid="b4" class=" bibr popnode" role="button" aria-expanded="false" aria-haspopup="true">4</a>], with minor roles for CYP3A4 and CYP2C19 [<a href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC1884190/#b4" rid="b4" class=" bibr popnode" role="button" aria-expanded="false" aria-haspopup="true">4</a>]. In addition, rosuvastatin had no significant inhibitory effect on the major CYP isoforms in human hepatic microsomes [<a href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC1884190/#b4" rid="b4" class=" bibr popnode" role="button" aria-expanded="false" aria-haspopup="true">4</a>].</p><p id="__p8">Some of the other HMG-CoA reductase inhibitors (atorvastatin [<a href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC1884190/#b5" rid="b5" class=" bibr popnode" role="button" aria-expanded="false" aria-haspopup="true">5</a>], simvastatin [<a href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC1884190/#b6" rid="b6" class=" bibr popnode tag_hotlink tag_tooltip" id="__tag_130180319" role="button" aria-expanded="false" aria-haspopup="true">6</a>], and lovastatin [<a href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC1884190/#b7" rid="b7" class=" bibr popnode tag_hotlink tag_tooltip" id="__tag_130180330" role="button" aria-expanded="false" aria-haspopup="true">7</a>]) are cleared primarily by metabolism involving CYP3A4. Thus, there is potential for interactions between these compounds and coadministered drugs affecting CYP3A4 activity. It has been shown that the metabolism of atorvastatin [<a href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC1884190/#b8" rid="b8" class=" bibr popnode tag_hotlink tag_tooltip" id="__tag_130180318" role="button" aria-expanded="false" aria-haspopup="true">8</a>–<a href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC1884190/#b10" rid="b10" class=" bibr popnode tag_hotlink tag_tooltip" id="__tag_130180331" role="button" aria-expanded="false" aria-haspopup="true">10</a>], simvastatin [<a href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC1884190/#b11" rid="b11" class=" bibr popnode tag_hotlink tag_tooltip" id="__tag_130180314" role="button" aria-expanded="false" aria-haspopup="true">11</a>, <a href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC1884190/#b12" rid="b12" class=" bibr popnode tag_hotlink tag_tooltip" id="__tag_130180315" role="button" aria-expanded="false" aria-haspopup="true">12</a>], and lovastatin [<a href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC1884190/#b13" rid="b13" class=" bibr popnode tag_hotlink tag_tooltip" id="__tag_130180321" role="button" aria-expanded="false" aria-haspopup="true">13</a>, <a href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC1884190/#b14" rid="b14" class=" bibr popnode tag_hotlink tag_tooltip" id="__tag_130180328" role="button" aria-expanded="false" aria-haspopup="true">14</a>] is inhibited by erythromycin and itraconazole, leading to increased serum/plasma drug concentrations and changes in their metabolic profiles.</p><p id="__p9">Although <em>in vitro</em> data suggest that CYP3A4 metabolism is not an important clearance mechanism for rosuvastatin, an <em>in vivo</em> interaction with coadministered drugs that inhibit CYP3A4 cannot be excluded. Accordingly, the present study was conducted to assess the effect of ketoconazole (a potent CYP3A4 inhibitor [<a href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC1884190/#b15" rid="b15" class=" bibr popnode tag_hotlink tag_tooltip" id="__tag_130180324" role="button" aria-expanded="false" aria-haspopup="true">15</a>]) on the pharmacokinetics of rosuvastatin.</p><p id="__p10" class="p p-last">Ketoconazole is also known to inhibit the activity of transport protein P-glycoprotein (P-gp) [<a href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC1884190/#b16" rid="b16" class=" bibr popnode tag_hotlink tag_tooltip" id="__tag_130180327" role="button" aria-expanded="false" aria-haspopup="true">16</a>]. Active- or facilitated-transport processes may have a role in the absorption and disposition of rosuvastatin. Thus, studies with rats have demonstrated selective hepatic uptake of rosuvastatin by an active transport process [<a href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC1884190/#b17" rid="b17" class=" bibr popnode" role="button" aria-expanded="false" aria-haspopup="true">17</a>], and rosuvastatin was shown to be a ligand for a liver-specific human organic-anion-transporting polypeptide present in the basolateral membranes of hepatic cells [<a href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC1884190/#b18" rid="b18" class=" bibr popnode" role="button" aria-expanded="false" aria-haspopup="true">18</a>], although the identity of these transporters has not yet been clearly defined. Thus, the results of the present study may provide an indication of whether P-gp-mediated transport contributes to rosuvastatin disposition.</p></div><div id="__sec6" class="tsec sec"><div class="goto jig-ncbiinpagenav-goto-container" id="ui-jig-11"><a class="tgt_dark page-toc-label jig-ncbiinpagenav-goto-heading" href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC1884190/#" title="Go to other sections in this page" role="button" aria-expanded="false" aria-haspopup="true" id="ui-jig-12">Go to:</a></div><h2 class="head no_bottom_margin ui-helper-clearfix" id="__sec6title">Methods</h2><p id="__p11" class="p p-first">This trial was conducted in accordance with good clinical practice and the Declaration of Helsinki. All volunteers gave written informed consent, and a local independent ethics committee approved the protocol before the trial started.</p><div id="__sec7" class="sec"><h3>Trial population</h3><p id="__p12" class="p p-first">Healthy adult (18–65 years) male volunteers with no clinically relevant conditions identified from their medical history, physical examination, or electrocardiogram (ECG) were included in the trial. Volunteers were excluded if they had any clinically relevant abnormalities in clinical chemistry, haematology, or urinalysis results, or if total bilirubin, alanine aminotransferase, aspartate aminotransferase, alkaline phosphatase, or creatine kinase were outside the normal reference range at the start of the trial.</p><p id="__p13" class="p p-last">Fourteen male Caucasian volunteers were enrolled. Their mean (range) age, height, and weight were 24.1 years (21–31), 182.1 cm (170–189), and 73.5 kg (60–83), respectively. Pharmacokinetic data were available from 13 volunteers [one volunteer withdrew due to personal reasons during the washout period following the first dosing period (rosuvastatin + placebo)]. This withdrawal was considered unlikely to have affected interpretation of the trial data.</p></div><div id="__sec8" class="sec"><h3>Trial design</h3><p id="__p14" class="p p-first">This randomized, double-blind, two-way crossover, placebo-controlled trial (4522IL/0057) was conducted at a single centre (AstraZeneca R&amp;D, Lund, Sweden). Volunteers were randomized to receive daily oral doses of ketoconazole 400 mg (1 × 200-mg tablet every 12 h) or matching placebo (one tablet every 12 h) for 7 days, with a 2-week washout period between dosing periods. On day 4 of each dosing period, volunteers were given a single oral dose of rosuvastatin 80 mg (1 × 80-mg encapsulated tablet) with the morning dose of ketoconazole or placebo. Volunteers then remained in the Clinical Pharmacology Unit for the following 24 h.</p><p id="__p15" class="p p-last">During the trial there were restrictions relating to the consumption of alcohol and physical exercise (none permitted from 96 h before the first dose on day 1 until 96 h after administration of rosuvastatin in each dosing period), the consumption of caffeine-containing drinks/food and smoking (none permitted from midnight before day 1 until 96 h after administration of rosuvastatin in each dosing period), and concomitant medications (none permitted from 96 h before the first dose on day 1 until after the post-trial medical).</p></div><div id="__sec9" class="sec"><h3>Determination of rosuvastatin plasma concentrations</h3><p id="__p16" class="p p-first">Blood samples (9 ml) for rosuvastatin assay were taken before administration of rosuvastatin on day 4 of each dosing period and 0.5, 1, 2, 3, 4, 5, 6, 8, 10, 12, 18, 24, 30, 48, 54, 72, and 96 h postdose. Additional samples were taken before administration of the first dose of ketoconazole or placebo on day 1 of the second dosing period. Blood samples were collected into tubes containing lithium heparin anticoagulant and centrifuged within 30 min. Plasma was then harvested from the samples, mixed 1:1 with sodium acetate buffer 0.1 <span class="small-caps">m</span> pH 4.0, and stored at −70°C until assay.</p><p id="__p17" class="p p-last">Plasma samples were analysed using a validated method (high-performance liquid chromatography with mass-spectrometric detection) at Quintiles Scotland Ltd (Edinburgh, UK) [<a href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC1884190/#b19" rid="b19" class=" bibr popnode tag_hotlink tag_tooltip" id="__tag_384404583" role="button" aria-expanded="false" aria-haspopup="true">19</a>]. Briefly, rosuvastatin was extracted from the samples by automated solid-phase extraction on 96-well plates containing a hydrophobic-lipophilic balanced copolymer sorbent using a Genesis RSP100 robotic sample-preparation system (Tecan, Reading, UK). The extract was injected onto a high-performance liquid chromatography column (a Luna column C<sub>18</sub>(2) 5 µm (4.6 mm i.d. × 150 mm l); the mobile phase was methanol : 0.2% formic acid in distilled water (70 : 30 v/v), and the flow rate was 1 ml min<sup>−1</sup>). Rosuvastatin was detected using a PE-Sciex API 365 triple quadruple mass spectrometer fitted with a turbo-ionspray source. The lower limit of quantification (LOQ) of rosuvastatin was verified as 0.1 ng ml<sup>−1</sup>. However, because all samples were diluted two-fold prior to assay, the effective LOQ was 0.2 ng ml<sup>−1</sup>. The coefficient of variation at the LOQ was ≤ 30%, and at 1 ng ml<sup>−1</sup> was ≤ 20%. Correlation coefficients for rosuvastatin calibration curves were 0.996-0.999. Mean imprecision values and inaccuracy levels for quality control samples were &lt; 9% and &lt; 6% (at all concentrations), respectively.</p></div><div id="__sec10" class="sec"><h3>Determination of HMG-CoA reductase inhibitor activity</h3><p id="__p18" class="p p-first">Two meaningful measures of circulating HMG-CoA reductase inhibitor activity are possible: active inhibitors (the sum of parent compound and active metabolites) and total inhibitors (the sum of parent compound, active metabolites, and inactive lactones). An interacting drug may affect the absolute concentrations of circulating active and/or total inhibitors, and possibly change the contribution of the parent compound to active and/or total inhibition.</p><p id="__p19" class="p p-last">The blood samples taken for rosuvastatin assay were also used to obtain plasma for active and total inhibitor assays. Samples were analysed using a validated method (radio-enzyme inhibition assay) at Medical Research Laboratories (Highland Heights, KT, USA). Briefly, drug-related components were isolated from plasma by using acetonitrile : acetone (95 : 5) to precipitate plasma proteins. The supernatant was assayed following hydrolysis (using potassium hydroxide to convert inactive lactones to active acids) for total inhibitors, and unhydrolysed for active inhibitors. The supernatant was evaporated to dryness under nitrogen, reconstituted with distilled water (50 µl), and incubated with buffer solution containing <sup>14</sup>C-HMG-CoA cofactors, and HMG-CoA reductase from a human recombinant source. The <sup>14</sup>C-mevalonate product of the enzyme reaction was separated from the substrate, after lactonization to <sup>14</sup>C-mevalonolactone by hydrochloric acid, on a small ion-exchange column. The effluent from the column (which contained the <sup>14</sup>C-mevalonolactone) was collected into scintillation vials and counted. The results were used to construct a standard curve. Concentrations are reported as ng equivalents of rosuvastatin ml<sup>−1</sup>. The lower LOQ was verified as 0.36 ng ml<sup>−1</sup> and the coefficient of variation at the LOQ was ≤ 15%. Mean imprecision values and inaccuracy levels for quality control samples were &lt; 11% and ≤ 16% (at all concentrations), respectively.</p></div><div id="__sec11" class="sec"><h3>Determination of ketoconazole plasma concentrations</h3><p id="__p20" class="p p-first">Blood samples (10 ml) were taken before and 2 h after administration of the first dose of ketoconazole or placebo on days 4, 5, 6 and 7 of each dosing period. Blood samples were collected into tubes containing EDTA anticoagulant and centrifuged. Plasma was then harvested from the samples and stored at −20°C until assay.</p><p id="__p21" class="p p-last">Plasma samples were analysed using a validated method, using high-performance liquid chromatography with fluorescence detection at Phoenix International Life Sciences Inc. (Montreal, Quebec, Canada). The lower LOQ was verified as 20 ng ml<sup>−1</sup>. Mean accuracy values for quality control samples were 96.5–104.8%, and the imprecision (coefficient of variation) was 1.5–2.5%.</p></div><div id="__sec12" class="sec"><h3>Pharmacokinetic parameters</h3><p id="__p22" class="p p-first">The primary parameters of this trial were area under the plasma concentration-time curve from time zero to infinity (AUC) and maximum observed plasma drug concentration (<em>C</em><sub>max</sub>) of rosuvastatin after dosing with ketoconazole compared with placebo. If less than 12 volunteers had AUC data available from both dosing periods, the area under the plasma concentration-time curve from time zero to the time of the last quantifiable concentration [AUC(0,<em>t</em>)] was substituted as a primary parameter for all volunteers. Secondary parameters included time to <em>C</em><sub>max</sub> (<em>t</em><sub>max</sub>), and terminal elimination half-life (<em>t</em><sub>½</sub>) of rosuvastatin, area under the plasma concentration-time curve and <em>C</em><sub>max</sub> of active and total HMG-CoA reductase inhibitors, and plasma drug concentration of ketoconazole before and 2 h after administration of the first dose on days 4–7.</p><p id="__p23" class="p p-last">AUC was determined using the linear trapezoidal rule from time zero to the time of the last quantifiable concentration followed by extrapolation to infinity using the terminal elimination rate constant (λ<sub>z</sub>, calculated by log-linear regression of the terminal portion of the plasma concentration-time curves). AUC(0,<em>t</em>) was determined using the linear trapezoidal rule. <em>C</em><sub>max</sub> and <em>t</em><sub>max</sub> were determined by visual inspection of the plasma concentration-time curves, <em>t</em><sub>½</sub> was calculated from the expression 0.693/λ<sub>z</sub>.</p></div><div id="__sec13" class="sec"><h3>Statistical methods</h3><p id="__p24" class="p p-first">The trial had more than 90% power to ensure that the 90% confidence interval (CI) for the treatment ratio (rosuvastatin + ketoconazole/rosuvastatin + placebo) of the geometric least square means (gls<sub>means</sub>) for rosuvastatin AUC [or AUC(0,<em>t</em>)] was contained within the interval of 0.7–1.43 (which represented an increase of 43% or a decrease of 30%). If the 90% CI fell within this prespecified interval, the absence of an interaction was assumed [<a href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC1884190/#b20" rid="b20" class=" bibr popnode tag_hotlink tag_tooltip" id="__tag_130180320" role="button" aria-expanded="false" aria-haspopup="true">20</a>].</p><p id="__p25" class="p p-last">As rosuvastatin AUC [or AUC(0,<em>t</em>)] and <em>C</em><sub>max</sub> were the primary parameters upon which sizing of the trial was based, only these were analysed statistically. The parameters were log-transformed and analysed using an analysis of variance model (<span class="small-caps">anova</span>), which accounted for the effects of volunteer, period, and treatment. The results are presented as gls<sub>means</sub>, treatment ratios, and the 90% CIs on the treatment ratios.</p></div><div id="__sec14" class="sec sec-last"><h3>Safety assessments</h3><p id="__p26" class="p p-first-last">The following safety assessments were performed: adverse event reports, clinical laboratory data (clinical chemistry, haematology, and urinalysis), vital signs, ECGs, and medical examinations.</p></div></div><div id="__sec15" class="tsec sec"><div class="goto jig-ncbiinpagenav-goto-container" id="ui-jig-13"><a class="tgt_dark page-toc-label jig-ncbiinpagenav-goto-heading" href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC1884190/#" title="Go to other sections in this page" role="button" aria-expanded="false" aria-haspopup="true" id="ui-jig-14">Go to:</a></div><h2 class="head no_bottom_margin ui-helper-clearfix" id="__sec15title">Results</h2><p id="__p27" class="p p-first">The geometric mean (g<sub>mean</sub>) plasma concentrations of rosuvastatin over time were similar when rosuvastatin was coadministered with ketoconazole and placebo (<a href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC1884190/figure/fig01/" target="figure" class="fig-table-link fig figpopup" rid-figpopup="fig01" rid-ob="ob-fig01" co-legend-rid="lgnd_fig01"><span>Figure 1</span></a>). As AUC data from both dosing periods were available for less than 12 volunteers, AUC(0,<em>t</em>) was substituted as a primary parameter and subjected to statistical analysis. AUC(0,<em>t</em>) represented a high proportion (on average 96.8%) of AUC (where it was possible to determine a reliable value), and thus was considered to be a suitable replacement for AUC in the assessment of exposure. Following coadministration with ketoconazole, rosuvastatin gls<sub>mean</sub> AUC(0,<em>t</em>) and <em>C</em><sub>max</sub> were unchanged compared with placebo (<a href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC1884190/table/tbl1/" target="true" class="fig-table-link table figpopup" rid-figpopup="tbl1" rid-ob="ob-tbl1" co-legend-rid=""><span>Table 1</span></a>). The 90% CIs for the treatment ratios fell within the prespecified interval of 0.7–1.43, so it was concluded that ketoconazole had no effect on the pharmacokinetics of rosuvastatin.</p><!--fig ft0--><!--fig mode=article f1--><div class="fig iconblock ten_col whole_rhythm clearfix" id="fig01" co-legend-rid="lgnd_fig01"><a class="icnblk_img figpopup" href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC1884190/figure/fig01/" target="figure" rid-figpopup="fig01" rid-ob="ob-fig01"><img src="./PMC1884190_files/bcp0055-0094-f1.gif" class="small-thumb" alt="Figure 1" title="Figure 1" src-large="/pmc/articles/PMC1884190/bin/bcp0055-0094-f1.jpg"></a><div class="icnblk_cntnt" id="lgnd_fig01"><div><a class="figpopup" href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC1884190/figure/fig01/" target="figure" rid-figpopup="fig01" rid-ob="ob-fig01">Figure 1</a></div><!--caption a4--><div><span>Geometric mean plasma concentrations of rosuvastatin over time when coadministered with ketoconazole or placebo. ○, Rosuvastatin + ketoconazole; ▪, rosuvastatin + placebo.</span></div></div></div><!--table ft1--><!--table-wrap mode=article t1--><div class="table-wrap iconblock ten_col whole_rhythm clearfix" id="tbl1"><a href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC1884190/table/tbl1/" target="table" rid-ob="ob-tbl1" rid-figpopup="tbl1" class="table img_link icnblk_img figpopup"><img alt="Table 1" title="Table 1" class="small-thumb" src="./PMC1884190_files/saved_resource" src-large="/pmc/articles/PMC1884190/table/tbl1/?report=previmg"></a><div class="icnblk_cntnt"><div><a class="figpopup" href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC1884190/table/tbl1/" target="table" rid-figpopup="tbl1" rid-ob="ob-tbl1">Table 1</a></div><!--caption a4--><div><span>Summary pharmacokinetic parameters of rosuvastatin, and results of the statistical analysis of the plasma AUC(0,<em>t</em>) and <em>C</em><sub>max</sub> of rosuvastatin, when coadministered with ketoconazole and placebo</span></div></div></div><p id="__p28">Comparison of areas under the plasma concentration-time curves measured to a common point for rosuvastatin and active and total HMG-CoA reductase inhibitors indicated that, within the accuracy and precision s of the methods used, rosuvastatin accounted for essentially all of the circulating active inhibitors and most (&gt; 85%) of the total inhibitors (<a href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC1884190/figure/fig02/" target="figure" class="fig-table-link fig figpopup" rid-figpopup="fig02" rid-ob="ob-fig02" co-legend-rid="lgnd_fig02"><span>Figure 2</span></a>). The active inhibitors accounted for the majority (≥ 75%) of the total circulating inhibitors (<a href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC1884190/figure/fig02/" target="figure" class="fig-table-link fig figpopup" rid-figpopup="fig02" rid-ob="ob-fig02" co-legend-rid="lgnd_fig02"><span>Figure 2</span></a>). Ketoconazole did not affect the proportion of circulating active or total HMG-CoA reductase inhibitors accounted for by circulating rosuvastatin.</p><!--fig ft0--><!--fig mode=article f1--><div class="fig iconblock ten_col whole_rhythm clearfix" id="fig02" co-legend-rid="lgnd_fig02"><a class="icnblk_img figpopup" href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC1884190/figure/fig02/" target="figure" rid-figpopup="fig02" rid-ob="ob-fig02"><img src="./PMC1884190_files/bcp0055-0094-f2.gif" class="small-thumb" alt="Figure 2" title="Figure 2" src-large="/pmc/articles/PMC1884190/bin/bcp0055-0094-f2.jpg"></a><div class="icnblk_cntnt" id="lgnd_fig02"><div><a class="figpopup" href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC1884190/figure/fig02/" target="figure" rid-figpopup="fig02" rid-ob="ob-fig02">Figure 2</a></div><!--caption a4--><div><span>Geometric mean plasma concentrations of active and total HMG-CoA reductase inhibitors and rosuvastatin over time when rosuvastatin was coadministered with ketoconazole. A similar pattern was seen when rosuvastatin was coadministered with placebo. ○,</span> <strong>...</strong></div></div></div><p id="__p29">The g<sub>mean</sub> plasma concentrations of ketoconazole before administration of the first dose on days 4–7 (data not shown) indicated that steady state was achieved before dosing with rosuvastatin and was maintained during sampling. The g<sub>mean</sub> plasma concentrations of ketoconazole 2 h after administration of the first dose on days 4–7 (4522, 6060, 6060, 5352 ng ml<sup>−1</sup>, respectively) suggested that concentrations fell within the range anticipated for a 200-mg dose of ketoconazole.</p><p id="__p30" class="p p-last">Rosuvastatin and ketoconazole were well tolerated when coadministered. There were no serious adverse events and no clinically relevant changes in clinical laboratory parameters, vital signs, ECGs, or medical examinations during this trial.</p></div><div id="__sec16" class="tsec sec"><div class="goto jig-ncbiinpagenav-goto-container" id="ui-jig-15"><a class="tgt_dark page-toc-label jig-ncbiinpagenav-goto-heading" href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC1884190/#" title="Go to other sections in this page" role="button" aria-expanded="false" aria-haspopup="true" id="ui-jig-16">Go to:</a></div><h2 class="head no_bottom_margin ui-helper-clearfix" id="__sec16title">Discussion</h2><p id="__p31" class="p p-first">Coadministration of rosuvastatin and the potent CYP3A4 inhibitor ketoconazole did not produce any change in pharmacokinetics of the former. Furthermore, the results suggest that ketoconazole had no effect on the systemic clearance of rosuvastatin, as individual plasma concentration profiles, including the terminal elimination phase (where defined), were similar between dosing periods.</p><p id="__p32">In contrast to rosuvastatin, atorvastatin [<a href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC1884190/#b5" rid="b5" class=" bibr popnode" role="button" aria-expanded="false" aria-haspopup="true">5</a>], simvastatin [<a href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC1884190/#b6" rid="b6" class=" bibr popnode tag_hotlink tag_tooltip" id="__tag_130180326" role="button" aria-expanded="false" aria-haspopup="true">6</a>], and lovastatin [<a href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC1884190/#b7" rid="b7" class=" bibr popnode tag_hotlink tag_tooltip" id="__tag_130180329" role="button" aria-expanded="false" aria-haspopup="true">7</a>] are cleared primarily by metabolism involving CYP3A4 and are known to interact with CYP3A4 inhibitors [<a href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC1884190/#b8" rid="b8" class=" bibr popnode tag_hotlink tag_tooltip" id="__tag_130180311" role="button" aria-expanded="false" aria-haspopup="true">8</a>–<a href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC1884190/#b14" rid="b14" class=" bibr popnode tag_hotlink tag_tooltip" id="__tag_130180325" role="button" aria-expanded="false" aria-haspopup="true">14</a>]. The increased circulating concentrations of these HMG-CoA reductase inhibitors reported following coadministration with CYP3A4 inhibitors may enhance the risk for serious adverse events such as skeletal muscle toxicity [<a href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC1884190/#b12" rid="b12" class=" bibr popnode tag_hotlink tag_tooltip" id="__tag_130180317" role="button" aria-expanded="false" aria-haspopup="true">12</a>, <a href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC1884190/#b14" rid="b14" class=" bibr popnode tag_hotlink tag_tooltip" id="__tag_130180323" role="button" aria-expanded="false" aria-haspopup="true">14</a>].</p><p id="__p33">Circulating active and total HMG-CoA reductase inhibitor concentrations were measured in this trial. The finding that rosuvastatin accounted for essentially all of the circulating active inhibitors suggests the presence of only a small amount of circulating metabolite(s). The finding that the active inhibitors, and therefore rosuvastatin, constituted the majority of the total inhibitors indicates the presence of only a small proportion of circulating drug-related species with the potential to generate pharmacologically active species (i.e. lactones). These results provide good support for previous data indicating limited metabolism of rosuvastatin [<a href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC1884190/#b3" rid="b3" class=" bibr popnode" role="button" aria-expanded="false" aria-haspopup="true">3</a>, <a href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC1884190/#b4" rid="b4" class=" bibr popnode" role="button" aria-expanded="false" aria-haspopup="true">4</a>].</p><p id="__p34">Other HMG-CoA reductase inhibitors have circulating metabolites that contribute significantly to inhibitory activity. Following coadministration with a CYP3A4 inhibitor, the absolute concentrations of HMG-CoA reductase inhibitors and the relative proportions of the parent compound and its metabolites may be affected. For example, in the case of atorvastatin, following coadministration with itraconazole, the mean AUC(0,72) of the active and total inhibitors was increased 1.6- and 1.7-fold, respectively; the mean AUC(0,72) of atorvastatin acid and lactone was increased 3.2- and 4.1-fold, respectively; and the mean AUC(0,72) of the principal metabolite 2-hydroxyatorvastatin acid and its lactone was decreased by 57% and 38%, respectively [<a href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC1884190/#b10" rid="b10" class=" bibr popnode tag_hotlink tag_tooltip" id="__tag_130180313" role="button" aria-expanded="false" aria-haspopup="true">10</a>].</p><p id="__p35">There is increasing awareness that drug interactions can also occur as a result of competition for, or induction or inhibition of, transport proteins. Ketoconazole is known to have inhibitory effects on the transport protein P-gp [<a href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC1884190/#b16" rid="b16" class=" bibr popnode tag_hotlink tag_tooltip" id="__tag_130180322" role="button" aria-expanded="false" aria-haspopup="true">16</a>]. Active- or facilitated-transport processes may have a role in the absorption and disposition of rosuvastatin [<a href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC1884190/#b17" rid="b17" class=" bibr popnode" role="button" aria-expanded="false" aria-haspopup="true">17</a>, <a href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC1884190/#b18" rid="b18" class=" bibr popnode" role="button" aria-expanded="false" aria-haspopup="true">18</a>]. The identity of the rosuvastatin transporters that interact with rosuvastatin has not been clearly defined, but if it were a P-gp substrate, an increase in rosuvastatin exposure would be expected following coadministration with ketoconazole. The potency of ketoconazole to inhibit P-gp has been assessed in cell-based assays and <em>in vivo</em> animal experiments [<a href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC1884190/#b16" rid="b16" class=" bibr popnode tag_hotlink tag_tooltip" id="__tag_130180312" role="button" aria-expanded="false" aria-haspopup="true">16</a>]. Based on these data, it is likely that the concentrations of ketoconazole achieved in the present study would have caused a degree of P-gp inhibition [<a href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC1884190/#b16" rid="b16" class=" bibr popnode tag_hotlink tag_tooltip" id="__tag_130180332" role="button" aria-expanded="false" aria-haspopup="true">16</a>]. Therefore, our results suggest that rosuvastatin is not a ligand for P-gp. This finding is in agreement with the results of a study that showed no effect of rosuvastatin on the pharmacokinetics of the P-gp substrate digoxin [<a href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC1884190/#b21" rid="b21" class=" bibr popnode tag_hotlink tag_tooltip" id="__tag_341082010" role="button" aria-expanded="false" aria-haspopup="true">21</a>].</p><p id="__p36" class="p p-last">In conclusion, ketoconazole did not affect the pharmacokinetics of rosuvastatin in healthy subjects. Therefore, coadministration of ketoconazole and rosuvastatin is unlikely to increase the risk of toxicity at therapeutic doses of rosuvastatin. The data suggest that neither cytochrome P450 3A4 nor P-gp-mediated transport contributes to the elimination of rosuvastatin.</p></div><div id="__ackid238192" class="tsec sec"><div class="goto jig-ncbiinpagenav-goto-container" id="ui-jig-17"><a class="tgt_dark page-toc-label jig-ncbiinpagenav-goto-heading" href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC1884190/#" title="Go to other sections in this page" role="button" aria-expanded="false" aria-haspopup="true" id="ui-jig-18">Go to:</a></div><h2 class="head no_bottom_margin ui-helper-clearfix" id="__ackid238192title">Acknowledgments</h2><div class="sec"><p id="__p37">The authors thank Quintiles Scotland Ltd (Edinburgh, UK) for performing the rosuvastatin assays, Medical Research Laboratories (Highland Heights, Kentucky, USA) for performing the HMG-CoA reductase inhibitor assays, Phoenix International Life Sciences Inc. (Montreal, Quebec, Canada) for performing the ketoconazole assays, Olise M. Nwose MB BS for his support of this trial, and Elizabeth Eaton PhD for manuscript preparation.</p></div></div><div id="__ref-listid238202" class="tsec sec"><div class="goto jig-ncbiinpagenav-goto-container" id="ui-jig-19"><a class="tgt_dark page-toc-label jig-ncbiinpagenav-goto-heading" href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC1884190/#" title="Go to other sections in this page" role="button" aria-expanded="false" aria-haspopup="true" id="ui-jig-20">Go to:</a></div><h2 class="head no_bottom_margin ui-helper-clearfix" id="__ref-listid238202title">References</h2><div class="ref-list-sec sec" id="reference-list"><div class="ref-cit-blk half_rhythm" id="b1">1. <span class="citation">Olsson AG, Pears J, McKellar J, Mizan J, Raza A. Effect of rosuvastatin on low-density lipoprotein cholesterol in patients with hypercholesterolemia. <span><span class="ref-journal">Am J Cardiol. </span>2001;<span class="ref-vol">88</span>:504–508.</span>  <span class="nowrap ref pubmed">[<a href="http://www.ncbi.nlm.nih.gov/pubmed/11524058" target="pmc_ext" ref="reftype=pubmed&amp;article-id=1884190&amp;issue-id=144659&amp;journal-id=279&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord&amp;rendering-type=normal">PubMed</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="b2">2. <span class="citation">Martin PD, Dane AL, Nwose OM, Schneck DW, Warwick MJ. No effect of age or gender on the pharmacokinetics of rosuvastatin—a new HMG-CoA reductase inhibitor. <span><span class="ref-journal">J Clin Pharmacol. </span>2002</span> in press.  <span class="nowrap ref pubmed">[<a href="http://www.ncbi.nlm.nih.gov/pubmed/12362926" target="pmc_ext" ref="reftype=pubmed&amp;article-id=1884190&amp;issue-id=144659&amp;journal-id=279&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord&amp;rendering-type=normal">PubMed</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="b3">3. <span class="citation">Martin PD, Dane AL, Schneck DW, Warwick MJ. Disposition of new HMG-CoA reductase inhibitor ZD4522 following dosing in healthy subjects. <span><span class="ref-journal">J Clin Pharmacol. </span>2000;<span class="ref-vol">40</span>:1056.</span> [Abstr. 48]</span></div><div class="ref-cit-blk half_rhythm" id="b4">4. <span class="citation">McCormick AD, McKillop D, Butters CJ, et al.  ZD4522—an HMG-CoA reductase inhibitor free of metabolically mediated drug interactions: metabolic studies in human <em>in vitro</em> systems. <span><span class="ref-journal">J Clin Pharmacol. </span>2000;<span class="ref-vol">40</span>:1055.</span> [Abstr. 46]</span></div><div class="ref-cit-blk half_rhythm" id="b5">5. <span class="citation">Michniewicz BM, Black AE, Sinz MW, Woolf TF. <em>In vitro</em> and <em>in vivo</em> metabolism of atorvastatin (CI-981) l. <span><span class="ref-journal">ISSX Proc. </span>1994;<span class="ref-vol">6</span>:93.</span></span></div><div class="ref-cit-blk half_rhythm" id="b6">6. <span class="citation">Prueksaritanont T, Gorham LM, Ma B, et al.  <em>In vitro</em> metabolism of simvastatin in humans (SBT) identification of metabolizing enzymes and effect of the drug on hepatic P450s. <span><span class="ref-journal">Drug Metab Dispos. </span>1997;<span class="ref-vol">25</span>:1191–1199.</span>  <span class="nowrap ref pubmed">[<a href="http://www.ncbi.nlm.nih.gov/pubmed/9321523" target="pmc_ext" ref="reftype=pubmed&amp;article-id=1884190&amp;issue-id=144659&amp;journal-id=279&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord&amp;rendering-type=normal">PubMed</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="b7">7. <span class="citation">Jacobsen W, Kirchner G, Hallensleben K, et al.  Comparison of cytochrome P-450-dependent metabolism and drug interactions of the 3-hydroxy-3-methylglutaryl-CoA reductase inhibitors lovastatin and pravastatin in the liver. <span><span class="ref-journal">Drug Metab Dispos. </span>1999;<span class="ref-vol">27</span>:173–179.</span>  <span class="nowrap ref pubmed">[<a href="http://www.ncbi.nlm.nih.gov/pubmed/9929499" target="pmc_ext" ref="reftype=pubmed&amp;article-id=1884190&amp;issue-id=144659&amp;journal-id=279&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord&amp;rendering-type=normal">PubMed</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="b8">8. <span class="citation">Siedlik PH, Olson SC, Yang B-B, Stern RH. Erythromycin coadministration increases plasma atorvastatin concentrations. <span><span class="ref-journal">J Clin Pharmacol. </span>1999;<span class="ref-vol">39</span>:501–504.</span>  <span class="nowrap ref pubmed">[<a href="http://www.ncbi.nlm.nih.gov/pubmed/10234598" target="pmc_ext" ref="reftype=pubmed&amp;article-id=1884190&amp;issue-id=144659&amp;journal-id=279&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord&amp;rendering-type=normal">PubMed</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="b9">9. <span class="citation">Mazzu AL, Lasseter KC, Shamblen EC, Agarwal V, Lettieri J, Sundaresen P. Itraconazole alters the pharmacokinetics of atorvastatin to a greater extent than either cerivastatin or pravastatin. <span><span class="ref-journal">Clin Pharmacol Ther. </span>2000;<span class="ref-vol">68</span>:391–400.</span>  <span class="nowrap ref pubmed">[<a href="http://www.ncbi.nlm.nih.gov/pubmed/11061579" target="pmc_ext" ref="reftype=pubmed&amp;article-id=1884190&amp;issue-id=144659&amp;journal-id=279&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord&amp;rendering-type=normal">PubMed</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="b10">10. <span class="citation">Kantola T, Kivistö KT, Neuvonen PJ. Effect of itraconazole on the pharmacokinetics of atorvastatin. <span><span class="ref-journal">Clin Pharmacol Ther. </span>1998;<span class="ref-vol">64</span>:58–65.</span>  <span class="nowrap ref pubmed">[<a href="http://www.ncbi.nlm.nih.gov/pubmed/9695720" target="pmc_ext" ref="reftype=pubmed&amp;article-id=1884190&amp;issue-id=144659&amp;journal-id=279&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord&amp;rendering-type=normal">PubMed</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="b11">11. <span class="citation">Kantola T, Kivistõ KT, Neuvonen PJ. Erythromycin and verapamil considerably increase serum simvastatin and simvastatin acid concentrations. <span><span class="ref-journal">Clin Pharmacol Ther. </span>1998;<span class="ref-vol">64</span>:177–182.</span>  <span class="nowrap ref pubmed">[<a href="http://www.ncbi.nlm.nih.gov/pubmed/9728898" target="pmc_ext" ref="reftype=pubmed&amp;article-id=1884190&amp;issue-id=144659&amp;journal-id=279&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord&amp;rendering-type=normal">PubMed</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="b12">12. <span class="citation">Neuvonen PJ, Kantola T, Kivistö KT. Simvastatin but not pravastatin is very susceptible to interaction with the CYP3A4 inhibitor itraconazole. <span><span class="ref-journal">Clin Pharmacol Ther. </span>1998;<span class="ref-vol">63</span>:332–341.</span>  <span class="nowrap ref pubmed">[<a href="http://www.ncbi.nlm.nih.gov/pubmed/9542477" target="pmc_ext" ref="reftype=pubmed&amp;article-id=1884190&amp;issue-id=144659&amp;journal-id=279&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord&amp;rendering-type=normal">PubMed</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="b13">13. <span class="citation">Kivistö KT, Kantola T, Neuvonen PJ. Different effects of itraconazole on the pharmacokinetics of fluvastatin and lovastatin. <span><span class="ref-journal">Br J Clin Pharmacol. </span>1998;<span class="ref-vol">46</span>:49–53.</span> <span class="nowrap ref pmc">[<a class="int-reflink" href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC1873980/">PMC free article</a>]</span>  <span class="nowrap ref pubmed">[<a href="http://www.ncbi.nlm.nih.gov/pubmed/9690949" target="pmc_ext" ref="reftype=pubmed&amp;article-id=1884190&amp;issue-id=144659&amp;journal-id=279&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord&amp;rendering-type=normal">PubMed</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="b14">14. <span class="citation">Neuvonen PJ, Jalava KM. Itraconazole drastically increases plasma concentrations of lovastatin and lovastatin acid. <span><span class="ref-journal">Clin Pharmacol Ther. </span>1996;<span class="ref-vol">60</span>:54–61.</span>  <span class="nowrap ref pubmed">[<a href="http://www.ncbi.nlm.nih.gov/pubmed/8689812" target="pmc_ext" ref="reftype=pubmed&amp;article-id=1884190&amp;issue-id=144659&amp;journal-id=279&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord&amp;rendering-type=normal">PubMed</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="b15">15. <span class="citation">Albengres E, Le Louët H, Tillement J-P. Systemic antifungal agents. Drug interactions of clinical significance. <span><span class="ref-journal">Drug Saf. </span>1998;<span class="ref-vol">18</span>:83–97.</span>  <span class="nowrap ref pubmed">[<a href="http://www.ncbi.nlm.nih.gov/pubmed/9512916" target="pmc_ext" ref="reftype=pubmed&amp;article-id=1884190&amp;issue-id=144659&amp;journal-id=279&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord&amp;rendering-type=normal">PubMed</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="b16">16. <span class="citation">Venkatakrishnan K, von Moltke LL, Greenblatt DJ. Effects of the antifungal agents on oxidative drug metabolism. <span><span class="ref-journal">Clin Pharmacokinet. </span>2000;<span class="ref-vol">38</span>:111–180.</span>  <span class="nowrap ref pubmed">[<a href="http://www.ncbi.nlm.nih.gov/pubmed/10709776" target="pmc_ext" ref="reftype=pubmed&amp;article-id=1884190&amp;issue-id=144659&amp;journal-id=279&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord&amp;rendering-type=normal">PubMed</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="b17">17. <span class="citation">Nezasa K, Takeuchi M, Yukawa T, et al.  Tissue specific distribution of S-4522, a novel 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitor, to the liver in rats l. <span><span class="ref-journal">Xenobiotic Metab Dispos. </span>1998;<span class="ref-vol">13</span>(Suppl):S226.</span></span></div><div class="ref-cit-blk half_rhythm" id="b18">18. <span class="citation">Brown CDA, Windass A, Bleasby K, Lauffart B. Rosuvastatin is a high affinity substrate of hepatic organic anion transporter OATP-C l. <span><span class="ref-journal">Atheroscler Suppl. </span>2001;<span class="ref-vol">2</span>:90.</span> (P174)</span></div><div class="ref-cit-blk half_rhythm" id="b19">19. <span class="citation">Hull CK, Penman AD, Smith CK, Martin PD. Quantification of rosuvastatin in human plasma by automated solid-phase extraction using tandem mass-spectrometric detection. <span><span class="ref-journal">J Chromatogr B Biomed Appl. </span>2002</span> in press.  <span class="nowrap ref pubmed">[<a href="http://www.ncbi.nlm.nih.gov/pubmed/12007766" target="pmc_ext" ref="reftype=pubmed&amp;article-id=1884190&amp;issue-id=144659&amp;journal-id=279&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord&amp;rendering-type=normal">PubMed</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="b20">20. <span class="citation">Tucker GT, Houston JB, Huang S-M. Optimizing drug development: strategies to assess drug metabolism/transporter interaction potential—toward a consensus. <span><span class="ref-journal">Br J Clin Pharmacol. </span>2001;<span class="ref-vol">52</span>:107–117.</span> <span class="nowrap ref pmc">[<a class="int-reflink" href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2014497/">PMC free article</a>]</span>  <span class="nowrap ref pubmed">[<a href="http://www.ncbi.nlm.nih.gov/pubmed/11453898" target="pmc_ext" ref="reftype=pubmed&amp;article-id=1884190&amp;issue-id=144659&amp;journal-id=279&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord&amp;rendering-type=normal">PubMed</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="b21">21. <span class="citation">Martin PD, Kemp J, Dane AL, Warwick MJ, Schneck DW. No effect of rosuvastatin on the pharmacokinetics of digoxin in healthy volunteers l. <span><span class="ref-journal">Pharmacotherapy. </span>2001;<span class="ref-vol">21</span>:1255.</span>  <span class="nowrap ref pubmed">[<a href="http://www.ncbi.nlm.nih.gov/pubmed/12463730" target="pmc_ext" ref="reftype=pubmed&amp;article-id=1884190&amp;issue-id=144659&amp;journal-id=279&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord&amp;rendering-type=normal">PubMed</a>]</span></span></div></div></div><div style="display: none; width: 200px; top: -100px; left: -100px;" aria-live="assertive" aria-hidden="true" class="ui-helper-reset ui-ncbipopper-wrapper ui-ncbilinksmenu"><ul id="ui-ncbiinpagenav-2"><li><a href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC1884190/#__abstractid163722title">Abstract</a></li><li><a href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC1884190/#__sec5title">Introduction</a></li><li><a href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC1884190/#__sec6title">Methods</a></li><li><a href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC1884190/#__sec15title">Results</a></li><li><a href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC1884190/#__sec16title">Discussion</a></li><li><a href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC1884190/#__ackid238192title">Acknowledgments</a></li><li><a href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC1884190/#__ref-listid238202title">References</a></li></ul></div></div><!--post-content--><hr class="whole_rhythm no_bottom_margin"><div class="courtesy-note no_margin small">Articles from <span class="acknowledgment-journal-title">British Journal of Clinical Pharmacology</span> are provided here courtesy of <strong>British Pharmacological Society</strong></div></div>
            
            
        
            
        </div>
        <!-- Book content -->
    </div>
    
    <div id="rightcolumn" class="four_col col last">
        <!-- Custom content above discovery portlets -->
        <div class="col6">
            
        </div>
        
        <div xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance"><div class="try-button"><a href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC1884190/?report=reader"><img src="./PMC1884190_files/3838809" alt="PubReader format: click here to try"></a></div><div class="format-menu"><h2>Formats:</h2><ul><li class="selected">Article</li> | <li><a href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC1884190/?report=reader">PubReader</a></li> | <li class="epub-link"><a href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC1884190/epub/">ePub (beta)</a></li> | <li><a href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC1884190/pdf/bcp0055-0094.pdf">PDF (98K)</a></li> | <li><a href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC1884190/#" data-citationid="PMC1884190" class="citationexporter ctxp" role="button" aria-expanded="false" aria-haspopup="true">Citation</a></li></ul></div></div><div xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="share-buttons"><h2>Share</h2><ul><li class="facebook"><a href="https://www.facebook.com/sharer/sharer.php?u=http%3A%2F%2Fwww.ncbi.nlm.nih.gov%2Fpmc%2Farticles%2FPMC1884190%2F" role="button" aria-expanded="false" aria-haspopup="true" target="_blank"><img src="./PMC1884190_files/4047626" alt="Share on Facebook">
                             Facebook
                        </a></li><li class="twitter"><a href="https://twitter.com/intent/tweet?url=http%3A%2F%2Fwww.ncbi.nlm.nih.gov%2Fpmc%2Farticles%2FPMC1884190%2F&amp;text=Lack%20of%20effect%20of%20ketoconazole%20on%20the%20pharmacokinetics%20of%20rosuvastatin%20in%20healthy%20subjects" role="button" aria-expanded="false" aria-haspopup="true" target="_blank"><img src="./PMC1884190_files/4047627" alt="Share on Twitter">
                             Twitter
                        </a></li><li class="gplus"><a href="https://plus.google.com/share?url=http%3A%2F%2Fwww.ncbi.nlm.nih.gov%2Fpmc%2Farticles%2FPMC1884190%2F" role="button" aria-expanded="false" aria-haspopup="true" target="_blank"><img src="./PMC1884190_files/4047628" alt="Share on Google Plus">
                             Google+
                        </a></li></ul></div>
        
        <div id="ajax-portlets" data-pmid="12534645" data-aiid="1884190" data-aid="1884190" data-iid="144659" data-domainid="279" data-domain="brjclinpharm" data-accid="PMC1884190" data-md5="097d03ef45265370fe730c10eb4235a0">
<div class="portlet pubmed_favoritesad">
<div class="portlet_head">
<div class="portlet_title"><h3><span>Save items</span></h3></div>
<a name="Shutter" sid="1" href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC1884190/#" class="portlet_shutter ui-ncbitoggler-open" title="Show/hide content" remembercollapsed="true" pgsec_name="pmfavad" toggles="ui-portlet_content-23" role="button" aria-expanded="true" style="position: absolute; padding: 0px;"></a>
</div>
<div class="ui-helper-reset" aria-live="assertive"><div class="portlet_content ui-ncbitoggler ui-ncbitoggler-slave-open" id="ui-portlet_content-23" aria-hidden="false"><div xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
<input type="hidden" name="absid" id="absid" value="1884190"><div id="pubmed_favoritesad" class="empty" data-db="pmc">
<span role="menubar"><div class="ui-ncbisetswitch ltd-hover" role="menuitem" aria-expanded="false" aria-haspopup="true"><a href="http://www.ncbi.nlm.nih.gov/myncbi/collections/" class="jig-ncbisetswitch blind collink ltd-hover ui-ncbisetswitch-hasStar" id="favList" data-jigconfig="destSelector:&#39;#favUL&#39;,starExists:true,createCollectionUrl:&#39;#&#39;,manageCollectionsUrl:&#39;/myncbi/collections/&#39;"><span class="star"></span>Add to Favorites</a><a class="ui-ncbisetswitch-button ltd-hover" title="View more options" href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC1884190/#"><span class="ui-icon ui-icon-triangle-1-s ui-ncbisetswitch-down">View more options</span></a></div></span><div style="display: none; width: 200px; top: -100px; left: -100px;" aria-live="assertive" aria-hidden="true" class="ui-helper-reset ui-ncbipopper-wrapper ui-ncbilinksmenu ui-ncbisetswitch-popper"><ul id="favUL" class="ui-ncbisetswitch-options"></ul><ul class="ui-ncbisetswitch-actions"><li class="ui-ncbisetswitch-actions-create" style="display: block;"><a class="ui-ncbisetswitch-create-collection" href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC1884190/#">Create collection...</a></li><li class="ui-ncbisetswitch-actions-manage" style="display: block;"><a class="ui-ncbisetswitch-manage-collections" href="http://www.ncbi.nlm.nih.gov/myncbi/collections/">Manage collections...</a></li></ul></div>
</div>
<div class="colloading">loading</div>
<span id="submenu_AddToCollections"><form method="post"><input type="submit" class="button_apply" name="addtocollection" value="1"></form></span>
</div></div></div>
</div><div class="portlet">
<div class="portlet_head">
<div class="portlet_title"><h3><span>Similar articles in PubMed</span></h3></div>
<a name="Shutter" sid="1" href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC1884190/#" class="portlet_shutter ui-ncbitoggler-open" title="Show/hide content" remembercollapsed="true" pgsec_name="PBooksDiscovery_RA" toggles="ui-portlet_content-25" role="button" aria-expanded="true" style="position: absolute; padding: 0px;"></a>
</div>
<div class="ui-helper-reset" aria-live="assertive"><div class="portlet_content ui-ncbitoggler ui-ncbitoggler-slave-open" id="ui-portlet_content-25" aria-hidden="false">
<ul>
<li class="brieflinkpopper two_line">
<a class="brieflinkpopperctrl" href="http://www.ncbi.nlm.nih.gov/pubmed/12709722" ref="reftype=relart&amp;article-id=1884190&amp;issue-id=144659&amp;journal-id=279&amp;FROM=Article|RelatedArticles&amp;TO=Entrez|Pubmed|Record&amp;rendering-type=normal" role="button" aria-expanded="false" aria-haspopup="true">Effect of itraconazole on the pharmacokinetics of rosuvastatin.</a><span class="source">[Clin Pharmacol Ther. 2003]</span><div class="brieflinkpop ui-helper-reset ui-ncbipopper-wrapper ui-ncbipopper-basic" id="ui-brieflinkpop-27" aria-live="assertive" aria-hidden="true" style="top: -100px; left: -100px; display: none;">
<em xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="author">Cooper KJ, Martin PD, Dane AL, Warwick MJ, Schneck DW, Cantarini MV. </em><em xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="cit">Clin Pharmacol Ther. 2003 Apr; 73(4):322-9. </em>
</div>
</li>
<li class="brieflinkpopper two_line">
<a class="brieflinkpopperctrl" href="http://www.ncbi.nlm.nih.gov/pubmed/12451430" ref="reftype=relart&amp;article-id=1884190&amp;issue-id=144659&amp;journal-id=279&amp;FROM=Article|RelatedArticles&amp;TO=Entrez|Pubmed|Record&amp;rendering-type=normal" role="button" aria-expanded="false" aria-haspopup="true">The effect of fluconazole on the pharmacokinetics of rosuvastatin.</a><span class="source">[Eur J Clin Pharmacol. 2002]</span><div class="brieflinkpop ui-helper-reset ui-ncbipopper-wrapper ui-ncbipopper-basic" id="ui-brieflinkpop-29" aria-live="assertive" aria-hidden="true" style="top: -100px; left: -100px; display: none;">
<em xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="author">Cooper KJ, Martin PD, Dane AL, Warwick MJ, Schneck DW, Cantarini MV. </em><em xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="cit">Eur J Clin Pharmacol. 2002 Nov; 58(8):527-31. Epub 2002 Oct 3.</em>
</div>
</li>
<li class="brieflinkpopper two_line">
<a class="brieflinkpopperctrl" href="http://www.ncbi.nlm.nih.gov/pubmed/12682802" ref="reftype=relart&amp;article-id=1884190&amp;issue-id=144659&amp;journal-id=279&amp;FROM=Article|RelatedArticles&amp;TO=Entrez|Pubmed|Record&amp;rendering-type=normal" role="button" aria-expanded="false" aria-haspopup="true">The effect of erythromycin on the pharmacokinetics of rosuvastatin.</a><span class="source">[Eur J Clin Pharmacol. 2003]</span><div class="brieflinkpop ui-helper-reset ui-ncbipopper-wrapper ui-ncbipopper-basic" id="ui-brieflinkpop-31" aria-live="assertive" aria-hidden="true" style="top: -100px; left: -100px; display: none;">
<em xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="author">Cooper KJ, Martin PD, Dane AL, Warwick MJ, Raza A, Schneck DW. </em><em xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="cit">Eur J Clin Pharmacol. 2003 May; 59(1):51-6. Epub 2003 Apr 1.</em>
</div>
</li>
<li class="brieflinkpopper two_line">
<a class="brieflinkpopperctrl" href="http://www.ncbi.nlm.nih.gov/pubmed/12769127" ref="reftype=relart&amp;article-id=1884190&amp;issue-id=144659&amp;journal-id=279&amp;FROM=Article|RelatedArticles&amp;TO=Entrez|Pubmed|Record&amp;rendering-type=normal" role="button" aria-expanded="false" aria-haspopup="true">Rosuvastatin: a highly efficacious statin for the treatment of dyslipidaemia.</a><span class="source">[Expert Opin Investig Drugs. 2002]</span><div class="brieflinkpop ui-helper-reset ui-ncbipopper-wrapper ui-ncbipopper-basic" id="ui-brieflinkpop-33" aria-live="assertive" aria-hidden="true" style="top: -100px; left: -100px; display: none;">
<em xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="author">Davidson MH. </em><em xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="cit">Expert Opin Investig Drugs. 2002 Mar; 11(3):125-41. </em>
</div>
</li>
<li class="brieflinkpopper two_line">
<a class="brieflinkpopperctrl" href="http://www.ncbi.nlm.nih.gov/pubmed/12549990" ref="reftype=relart&amp;article-id=1884190&amp;issue-id=144659&amp;journal-id=279&amp;FROM=Article|RelatedArticles&amp;TO=Entrez|Pubmed|Record&amp;rendering-type=normal" role="button" aria-expanded="false" aria-haspopup="true">Rosuvastatin: a new HMG-CoA reductase inhibitor for the treatment of hypercholesterolemia.</a><span class="source">[Heart Dis. 2003]</span><div class="brieflinkpop ui-helper-reset ui-ncbipopper-wrapper ui-ncbipopper-basic" id="ui-brieflinkpop-35" aria-live="assertive" aria-hidden="true" style="top: -100px; left: -100px; display: none;">
<em xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="author">Cheng-Lai A. </em><em xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="cit">Heart Dis. 2003 Jan-Feb; 5(1):72-8. </em>
</div>
</li>
</ul>
<a class="seemore" href="http://www.ncbi.nlm.nih.gov/sites/entrez?db=pubmed&amp;cmd=link&amp;linkname=pubmed_pubmed_reviews&amp;uid=12534645&amp;log%24=relatedreviews&amp;logdbfrom=pmc" ref="reftype=relart&amp;article-id=1884190&amp;issue-id=144659&amp;journal-id=279&amp;FROM=Article|RelatedArticles&amp;TO=Entrez|Pubmed|Reviews&amp;rendering-type=normal">See reviews...</a><a class="seemore" href="http://www.ncbi.nlm.nih.gov/sites/entrez?db=pubmed&amp;cmd=link&amp;linkname=pubmed_pubmed&amp;uid=12534645&amp;log%24=relatedarticles&amp;logdbfrom=pmc" ref="reftype=relart&amp;article-id=1884190&amp;issue-id=144659&amp;journal-id=279&amp;FROM=Article|RelatedArticles&amp;TO=Entrez|Pubmed|Related%20Records&amp;rendering-type=normal">See all...</a>
</div></div>
</div><div class="portlet">
<div class="portlet_head">
<div class="portlet_title"><h3><span>Cited by other articles in PMC</span></h3></div>
<a name="Shutter" sid="1" href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC1884190/#" class="portlet_shutter ui-ncbitoggler-open" title="Show/hide content" remembercollapsed="true" pgsec_name="PMCVCitedByPmcArticlesP" toggles="ui-portlet_content-37" role="button" aria-expanded="true" style="position: absolute; padding: 0px;"></a>
</div>
<div class="ui-helper-reset" aria-live="assertive"><div class="portlet_content ui-ncbitoggler ui-ncbitoggler-slave-open" id="ui-portlet_content-37" aria-hidden="false">
<ul>
<li class="brieflinkpopper two_line">
<a class="brieflinkpopperctrl" href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4569258/" ref="reftype=relart&amp;article-id=1884190&amp;issue-id=144659&amp;journal-id=279&amp;FROM=Article|CitedByInPmc&amp;TO=PMC|Article|Record&amp;rendering-type=normal" role="button" aria-expanded="false" aria-haspopup="true">Optical Isomers of Atorvastatin, Rosuvastatin and Fluvastatin Enantiospecifically Activate Pregnane X Receptor PXR and Induce CYP2A6, CYP2B6 and CYP3A4 in Human Hepatocytes</a><span class="source">[PLoS ONE. 2015]</span><div class="brieflinkpop ui-helper-reset ui-ncbipopper-wrapper ui-ncbipopper-basic" id="ui-brieflinkpop-39" aria-live="assertive" aria-hidden="true" style="top: -100px; left: -100px; display: none;">
<em xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="author">Korhonova M, Doricakova A, Dvorak Z. </em><em xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="cit">PLoS ONE. 2015 Sep 14; 10(9)e0137720</em>
</div>
</li>
<li class="brieflinkpopper two_line">
<a class="brieflinkpopperctrl" href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4127422/" ref="reftype=relart&amp;article-id=1884190&amp;issue-id=144659&amp;journal-id=279&amp;FROM=Article|CitedByInPmc&amp;TO=PMC|Article|Record&amp;rendering-type=normal" role="button" aria-expanded="false" aria-haspopup="true">More potent lipid lowering effect by rosuvastatin compared to fluvastatin in everolimus treated renal transplant recipients</a><span class="source">[Transplantation. 2014]</span><div class="brieflinkpop ui-helper-reset ui-ncbipopper-wrapper ui-ncbipopper-basic" id="ui-brieflinkpop-41" aria-live="assertive" aria-hidden="true" style="top: -100px; left: -100px; display: none;">
<em xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="author">Robertsen I, Åsberg A, Granseth T, Vethe NT, Akhlaghi F, Ghareeb M, Molden E, Reier-Nilsen M, Holdaas H, Midtvedt K. </em><em xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="cit">Transplantation. 2014 Jun 27; 97(12)1266-1271</em>
</div>
</li>
<li class="brieflinkpopper two_line">
<a class="brieflinkpopperctrl" href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3967345/" ref="reftype=relart&amp;article-id=1884190&amp;issue-id=144659&amp;journal-id=279&amp;FROM=Article|CitedByInPmc&amp;TO=PMC|Article|Record&amp;rendering-type=normal" role="button" aria-expanded="false" aria-haspopup="true">Pharmacokinetics and tolerability of multiple-dose rosuvastatin: An open-label, randomized-sequence, three-way crossover trial in healthy Chinese volunteers</a><span class="source">[Current Therapeutic Research, ...]</span><div class="brieflinkpop ui-helper-reset ui-ncbipopper-wrapper ui-ncbipopper-basic" id="ui-brieflinkpop-43" aria-live="assertive" aria-hidden="true" style="top: -100px; left: -100px; display: none;">
<em xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="author">Zhang R, Li Y, Jiang X, Wang L. </em><em xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="cit">Current Therapeutic Research, Clinical and Experimental. 2009 Oct; 70(5)392-404</em>
</div>
</li>
<li class="brieflinkpopper two_line">
<a class="brieflinkpopperctrl" href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3836307/" ref="reftype=relart&amp;article-id=1884190&amp;issue-id=144659&amp;journal-id=279&amp;FROM=Article|CitedByInPmc&amp;TO=PMC|Article|Record&amp;rendering-type=normal" role="button" aria-expanded="false" aria-haspopup="true">Hepatic Basolateral Efflux Contributes Significantly to Rosuvastatin Disposition I: Characterization of Basolateral Versus Biliary Clearance Using a Novel Protocol in Sandwich-Cultured Hepatocytes</a><span class="source">[The Journal of Pharmacology an...]</span><div class="brieflinkpop ui-helper-reset ui-ncbipopper-wrapper ui-ncbipopper-basic" id="ui-brieflinkpop-45" aria-live="assertive" aria-hidden="true" style="top: -100px; left: -100px; display: none;">
<em xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="author">Pfeifer ND, Yang K, Brouwer KL. </em><em xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="cit">The Journal of Pharmacology and Experimental Therapeutics. 2013 Dec; 347(3)727-736</em>
</div>
</li>
<li class="brieflinkpopper two_line">
<a class="brieflinkpopperctrl" href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3149564/" ref="reftype=relart&amp;article-id=1884190&amp;issue-id=144659&amp;journal-id=279&amp;FROM=Article|CitedByInPmc&amp;TO=PMC|Article|Record&amp;rendering-type=normal" role="button" aria-expanded="false" aria-haspopup="true">Generation of polyclonal antibody with high avidity to rosuvastatin and its use in development of highly sensitive ELISA for determination of rosuvastatin in plasma</a><span class="source">[Chemistry Central Journal. 2011]</span><div class="brieflinkpop ui-helper-reset ui-ncbipopper-wrapper ui-ncbipopper-basic" id="ui-brieflinkpop-47" aria-live="assertive" aria-hidden="true" style="top: -100px; left: -100px; display: none;">
<em xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="author">Darwish IA, Al-Obaid AR, Al-Malaq HA. </em><em xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="cit">Chemistry Central Journal. 2011 Jul 5; 538</em>
</div>
</li>
</ul>
<a class="seemore" href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC1884190/citedby/" ref="reftype=relart&amp;article-id=1884190&amp;issue-id=144659&amp;journal-id=279&amp;FROM=Article|CitedByInPmc&amp;TO=PMC|Article|CitedBy&amp;rendering-type=normal">See all...</a>
</div></div>
</div><div class="portlet">
<div class="portlet_head">
<div class="portlet_title"><h3><span>Links</span></h3></div>
<a name="Shutter" sid="1" href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC1884190/#" class="portlet_shutter ui-ncbitoggler-open" title="Show/hide content" remembercollapsed="true" pgsec_name="PMCVCitedByPmcArticlesP" toggles="ui-portlet_content-49" role="button" aria-expanded="true" style="position: absolute; padding: 0px;"></a>
</div>
<div class="ui-helper-reset" aria-live="assertive"><div class="portlet_content ui-ncbitoggler ui-ncbitoggler-slave-open" id="ui-portlet_content-49" aria-hidden="false"><ul>
<li class="brieflinkpopper">
<a class="brieflinkpopperctrl" href="http://www.ncbi.nlm.nih.gov/pmc/?Db=pccompound&amp;DbFrom=pmc&amp;Cmd=Link&amp;LinkName=pmc_pccompound&amp;IdsFromResult=1884190" ref="reftype=Compound&amp;article-id=1884190&amp;issue-id=144659&amp;journal-id=279&amp;FROM=Article|DiscoveryLinks&amp;TO=Entrez|Crosslink|PubChem%20Compound&amp;rendering-type=normal" role="button" aria-expanded="false" aria-haspopup="true">Compound</a><div class="brieflinkpop ui-helper-reset ui-ncbipopper-wrapper ui-ncbipopper-basic" id="ui-brieflinkpop-51" aria-live="assertive" aria-hidden="true" style="top: -100px; left: -100px; display: none;">Compound<div class="brieflinkpopdesc">PubChem Compound links</div>
</div>
</li>
<li class="brieflinkpopper">
<a class="brieflinkpopperctrl" href="http://www.ncbi.nlm.nih.gov/pmc/?Db=medgen&amp;DbFrom=pmc&amp;Cmd=Link&amp;LinkName=pmc_medgen&amp;IdsFromResult=1884190" ref="reftype=MedGen&amp;article-id=1884190&amp;issue-id=144659&amp;journal-id=279&amp;FROM=Article|DiscoveryLinks&amp;TO=Entrez|Crosslink|Unknown%20Link%20Name&amp;rendering-type=normal" role="button" aria-expanded="false" aria-haspopup="true">MedGen</a><div class="brieflinkpop ui-helper-reset ui-ncbipopper-wrapper ui-ncbipopper-basic" id="ui-brieflinkpop-53" aria-live="assertive" aria-hidden="true" style="top: -100px; left: -100px; display: none;">MedGen<div class="brieflinkpopdesc">Related information in MedGen</div>
</div>
</li>
<li class="brieflinkpopper">
<a class="brieflinkpopperctrl" href="http://www.ncbi.nlm.nih.gov/pubmed/12534645/" ref="reftype=PubMed&amp;article-id=1884190&amp;issue-id=144659&amp;journal-id=279&amp;FROM=Article|DiscoveryLinks&amp;TO=Entrez|PubMed|Record&amp;rendering-type=normal" role="button" aria-expanded="false" aria-haspopup="true">PubMed</a><div class="brieflinkpop ui-helper-reset ui-ncbipopper-wrapper ui-ncbipopper-basic" id="ui-brieflinkpop-55" aria-live="assertive" aria-hidden="true" style="top: -100px; left: -100px; display: none;">PubMed<div class="brieflinkpopdesc">PubMed citations for these articles</div>
</div>
</li>
<li class="brieflinkpopper">
<a class="brieflinkpopperctrl" href="http://www.ncbi.nlm.nih.gov/pmc/?Db=pcsubstance&amp;DbFrom=pmc&amp;Cmd=Link&amp;LinkName=pmc_pcsubstance&amp;IdsFromResult=1884190" ref="reftype=Substance&amp;article-id=1884190&amp;issue-id=144659&amp;journal-id=279&amp;FROM=Article|DiscoveryLinks&amp;TO=Entrez|Crosslink|PubChem%20Substance&amp;rendering-type=normal" role="button" aria-expanded="false" aria-haspopup="true">Substance</a><div class="brieflinkpop ui-helper-reset ui-ncbipopper-wrapper ui-ncbipopper-basic" id="ui-brieflinkpop-57" aria-live="assertive" aria-hidden="true" style="top: -100px; left: -100px; display: none;">Substance<div class="brieflinkpopdesc">PubChem Substance links</div>
</div>
</li>
</ul></div></div>
</div><div class="portlet">
<div class="portlet_head">
<div class="portlet_title"><h3><span>Recent Activity</span></h3></div>
<a name="Shutter" sid="1" href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC1884190/#" class="portlet_shutter ui-ncbitoggler-open" title="Show/hide content" remembercollapsed="true" pgsec_name="recent_activity" toggles="ui-portlet_content-59" role="button" aria-expanded="true" style="position: absolute; padding: 0px;"></a>
</div>
<div class="ui-helper-reset" aria-live="assertive"><div class="portlet_content ui-ncbitoggler ui-ncbitoggler-slave-open" id="ui-portlet_content-59" aria-hidden="false"><div xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" id="HTDisplay" class="">
<div class="action">
<a href="javascript:historyDisplayState(&#39;ClearHT&#39;)">Clear</a><a href="javascript:historyDisplayState(&#39;HTOff&#39;)" class="HTOn">Turn Off</a><a href="javascript:historyDisplayState(&#39;HTOn&#39;)" class="HTOff">Turn On</a>
</div>
<ul id="activity">
<li class="ra_rcd ralinkpopper two_line">
<a class="htb ralinkpopperctrl" ref="log$=activity&amp;linkpos=1" href="http://www.ncbi.nlm.nih.gov/portal/utils/pageresolver.fcgi?recordid=576c26b37fd84438f0e9d38f">Lack of effect of ketoconazole on the pharmacokinetics of rosuvastatin in health...</a><div class="ralinkpop offscreen_noflow">Lack of effect of ketoconazole on the pharmacokinetics of rosuvastatin in healthy subjects<div class="brieflinkpopdesc">British Journal of Clinical Pharmacology. 2003 Jan; 55(1)94</div>
</div>
<div class="tertiary"></div>
</li>
<li class="ra_qry two_line">
<a class="htb" ref="log$=activity&amp;linkpos=2" href="http://www.ncbi.nlm.nih.gov/portal/utils/pageresolver.fcgi?recordid=576c26b07fd84438f0e9d332">PMC1884190 <span class="number">(1)</span></a><div class="tertiary">PMC</div>
</li>
<li class="ra_rcd ralinkpopper two_line">
<a class="htb ralinkpopperctrl" ref="log$=activity&amp;linkpos=3" href="http://www.ncbi.nlm.nih.gov/portal/utils/pageresolver.fcgi?recordid=576c269704fcfad5917683b7">Pharmacodynamic effects and pharmacokinetics of a new HMG-CoA reductase inhibito...</a><div class="ralinkpop offscreen_noflow">Pharmacodynamic effects and pharmacokinetics of a new HMG-CoA reductase inhibitor, rosuvastatin, after morning or evening administration in healthy volunteers<div class="brieflinkpopdesc">British Journal of Clinical Pharmacology. 2002 Nov; 54(5)472</div>
</div>
<div class="tertiary"></div>
</li>
<li class="ra_qry two_line">
<a class="htb" ref="log$=activity&amp;linkpos=4" href="http://www.ncbi.nlm.nih.gov/portal/utils/pageresolver.fcgi?recordid=576c26947fd84438f0e9ce66">PMC1874466 <span class="number">(1)</span></a><div class="tertiary">PMC</div>
</li>
<li class="ra_rcd ralinkpopper two_line">
<a class="htb ralinkpopperctrl" ref="log$=activity&amp;linkpos=5" href="http://www.ncbi.nlm.nih.gov/portal/utils/pageresolver.fcgi?recordid=576c267c04fcfad591767e80">The Risk of Overanticoagulation with Antibiotic Use in Outpatients on Stable War...</a><div class="ralinkpop offscreen_noflow">The Risk of Overanticoagulation with Antibiotic Use in Outpatients on Stable Warfarin Regimens<div class="brieflinkpopdesc">Journal of General Internal Medicine. 2005 Jul; 20(7)653</div>
</div>
<div class="tertiary"></div>
</li>
</ul>
<p class="HTOn">Your browsing activity is empty.</p>
<p class="HTOff">Activity recording is turned off.</p>
<p id="turnOn" class="HTOff"><a href="javascript:historyDisplayState(&#39;HTOn&#39;)">Turn recording back on</a></p>
<a class="seemore" href="http://www.ncbi.nlm.nih.gov/sites/myncbi/recentactivity">See more...</a>
</div></div></div>
</div>
<div>
<div class="portlet brieflink pmc_para_cit" id="crb--__p5" name="crb--__p5" rid="__p5" style="position: absolute; visibility: visible; width: 370px; top: 1033px; display: none;">
<div class="portlet_head"></div>
<div class="portlet_content" id="ui-portlet_content-61"><ul><li class="two_line" reference_id="b1">
<a href="http://www.ncbi.nlm.nih.gov/pubmed/11524058/" ref="reftype=pubmed&amp;article-id=1884190&amp;issue-id=144659&amp;journal-id=279&amp;FROM=Article|CitedRefBlock&amp;TO=Entrez|Pubmed|Record&amp;rendering-type=normal">Effect of rosuvastatin on low-density lipoprotein cholesterol in patients with hypercholesterolemia.</a><span class="one_line_source">[Am J Cardiol.  2001]</span><div class="alt-note">
<div class="authors">Olsson AG, Pears J, McKellar J, Mizan J, Raza A</div>
<div class="citation">Am J Cardiol. 2001 Sep 1; 88(5):504-8.</div>
</div>
</li></ul></div>
</div>
<div class="portlet brieflink pmc_para_cit" id="crb--__p6" name="crb--__p6" rid="__p6" style="position: absolute; visibility: visible; width: 370px; top: 1128px; display: none;">
<div class="portlet_head"></div>
<div class="portlet_content" id="ui-portlet_content-62"><ul><li class="two_line" reference_id="b2">
<a href="http://www.ncbi.nlm.nih.gov/pubmed/12362926/" ref="reftype=pubmed&amp;article-id=1884190&amp;issue-id=144659&amp;journal-id=279&amp;FROM=Article|CitedRefBlock&amp;TO=Entrez|Pubmed|Record&amp;rendering-type=normal">No effect of age or gender on the pharmacokinetics of rosuvastatin: a new HMG-CoA reductase inhibitor.</a><span class="one_line_source">[J Clin Pharmacol.  2002]</span><div class="alt-note">
<div class="authors">Martin PD, Dane AL, Nwose OM, Schneck DW, Warwick MJ</div>
<div class="citation">J Clin Pharmacol. 2002 Oct; 42(10):1116-21.</div>
</div>
</li></ul></div>
</div>
<div class="portlet brieflink pmc_para_cit" id="crb--__p8" name="crb--__p8" rid="__p8" style="position: absolute; visibility: visible; width: 370px; top: 1404px; display: none;">
<div class="portlet_head"></div>
<div class="portlet_content" id="ui-portlet_content-63"><ul>
<li class="two_line" reference_id="b6">
<a href="http://www.ncbi.nlm.nih.gov/pubmed/9321523/" ref="reftype=pubmed&amp;article-id=1884190&amp;issue-id=144659&amp;journal-id=279&amp;FROM=Article|CitedRefBlock&amp;TO=Entrez|Pubmed|Record&amp;rendering-type=normal">In vitro metabolism of simvastatin in humans [SBT]identification of metabolizing enzymes and effect of the drug on hepatic P450s.</a><span class="one_line_source">[Drug Metab Dispos.  1997]</span><div class="alt-note">
<div class="authors">Prueksaritanont T, Gorham LM, Ma B, Liu L, Yu X, Zhao JJ, Slaughter DE, Arison BH, Vyas KP</div>
<div class="citation">Drug Metab Dispos. 1997 Oct; 25(10):1191-9.</div>
</div>
</li>
<li class="two_line" reference_id="b7">
<a href="http://www.ncbi.nlm.nih.gov/pubmed/9929499/" ref="reftype=pubmed&amp;article-id=1884190&amp;issue-id=144659&amp;journal-id=279&amp;FROM=Article|CitedRefBlock&amp;TO=Entrez|Pubmed|Record&amp;rendering-type=normal">Comparison of cytochrome P-450-dependent metabolism and drug interactions of the 3-hydroxy-3-methylglutaryl-CoA reductase inhibitors lovastatin and pravastatin in the liver.</a><span class="one_line_source">[Drug Metab Dispos.  1999]</span><div class="alt-note">
<div class="authors">Jacobsen W, Kirchner G, Hallensleben K, Mancinelli L, Deters M, Hackbarth I, Benet LZ, Sewing KF, Christians U</div>
<div class="citation">Drug Metab Dispos. 1999 Feb; 27(2):173-9.</div>
</div>
</li>
<li class="two_line" reference_id="b8" style="display: none;">
<a href="http://www.ncbi.nlm.nih.gov/pubmed/10234598/" ref="reftype=pubmed&amp;article-id=1884190&amp;issue-id=144659&amp;journal-id=279&amp;FROM=Article|CitedRefBlock&amp;TO=Entrez|Pubmed|Record&amp;rendering-type=normal">Erythromycin coadministration increases plasma atorvastatin concentrations.</a><span class="one_line_source">[J Clin Pharmacol.  1999]</span><div class="alt-note">
<div class="authors">Siedlik PH, Olson SC, Yang BB, Stern RH</div>
<div class="citation">J Clin Pharmacol. 1999 May; 39(5):501-4.</div>
</div>
</li>
<li class="two_line" reference_id="b10" style="display: none;">
<a href="http://www.ncbi.nlm.nih.gov/pubmed/9695720/" ref="reftype=pubmed&amp;article-id=1884190&amp;issue-id=144659&amp;journal-id=279&amp;FROM=Article|CitedRefBlock&amp;TO=Entrez|Pubmed|Record&amp;rendering-type=normal">Effect of itraconazole on the pharmacokinetics of atorvastatin.</a><span class="one_line_source">[Clin Pharmacol Ther.  1998]</span><div class="alt-note">
<div class="authors">Kantola T, Kivistö KT, Neuvonen PJ</div>
<div class="citation">Clin Pharmacol Ther. 1998 Jul; 64(1):58-65.</div>
</div>
</li>
<li class="two_line" reference_id="b11" style="display: none;">
<a href="http://www.ncbi.nlm.nih.gov/pubmed/9728898/" ref="reftype=pubmed&amp;article-id=1884190&amp;issue-id=144659&amp;journal-id=279&amp;FROM=Article|CitedRefBlock&amp;TO=Entrez|Pubmed|Record&amp;rendering-type=normal">Erythromycin and verapamil considerably increase serum simvastatin and simvastatin acid concentrations.</a><span class="one_line_source">[Clin Pharmacol Ther.  1998]</span><div class="alt-note">
<div class="authors">Kantola T, Kivistö KT, Neuvonen PJ</div>
<div class="citation">Clin Pharmacol Ther. 1998 Aug; 64(2):177-82.</div>
</div>
</li>
<li class="two_line" reference_id="b12" style="display: none;">
<a href="http://www.ncbi.nlm.nih.gov/pubmed/9542477/" ref="reftype=pubmed&amp;article-id=1884190&amp;issue-id=144659&amp;journal-id=279&amp;FROM=Article|CitedRefBlock&amp;TO=Entrez|Pubmed|Record&amp;rendering-type=normal">Simvastatin but not pravastatin is very susceptible to interaction with the CYP3A4 inhibitor itraconazole.</a><span class="one_line_source">[Clin Pharmacol Ther.  1998]</span><div class="alt-note">
<div class="authors">Neuvonen PJ, Kantola T, Kivistö KT</div>
<div class="citation">Clin Pharmacol Ther. 1998 Mar; 63(3):332-41.</div>
</div>
</li>
<li class="two_line" reference_id="b13" style="display: none;">
<a href="http://www.ncbi.nlm.nih.gov/pubmed/9690949/" ref="reftype=pubmed&amp;article-id=1884190&amp;issue-id=144659&amp;journal-id=279&amp;FROM=Article|CitedRefBlock&amp;TO=Entrez|Pubmed|Record&amp;rendering-type=normal">Different effects of itraconazole on the pharmacokinetics of fluvastatin and lovastatin.</a><span class="one_line_source">[Br J Clin Pharmacol.  1998]</span><div class="alt-note">
<div class="authors">Kivistö KT, Kantola T, Neuvonen PJ</div>
<div class="citation">Br J Clin Pharmacol. 1998 Jul; 46(1):49-53.</div>
</div>
</li>
<li class="two_line" reference_id="b14" style="display: none;">
<a href="http://www.ncbi.nlm.nih.gov/pubmed/8689812/" ref="reftype=pubmed&amp;article-id=1884190&amp;issue-id=144659&amp;journal-id=279&amp;FROM=Article|CitedRefBlock&amp;TO=Entrez|Pubmed|Record&amp;rendering-type=normal">Itraconazole drastically increases plasma concentrations of lovastatin and lovastatin acid.</a><span class="one_line_source">[Clin Pharmacol Ther.  1996]</span><div class="alt-note">
<div class="authors">Neuvonen PJ, Jalava KM</div>
<div class="citation">Clin Pharmacol Ther. 1996 Jul; 60(1):54-61.</div>
</div>
</li>
</ul><a href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC1884190/" class="seemore">See more ...</a></div>
</div>
<div class="portlet brieflink pmc_para_cit" id="crb--__p9" name="crb--__p9" rid="__p9" style="position: absolute; visibility: visible; width: 370px; top: 1541px;">
<div class="portlet_head"></div>
<div class="portlet_content" id="ui-portlet_content-64"><ul><li class="two_line" reference_id="b15">
<a href="http://www.ncbi.nlm.nih.gov/pubmed/9512916/" ref="reftype=pubmed&amp;article-id=1884190&amp;issue-id=144659&amp;journal-id=279&amp;FROM=Article|CitedRefBlock&amp;TO=Entrez|Pubmed|Record&amp;rendering-type=normal"><span class="invert">Review</span> Systemic antifungal agents. Drug interactions of clinical significance.</a><span class="one_line_source">[Drug Saf.  1998]</span><div class="alt-note">
<div class="authors">Albengres E, Le Louët H, Tillement JP</div>
<div class="citation">Drug Saf. 1998 Feb; 18(2):83-97.</div>
</div>
</li></ul></div>
</div>
<div class="portlet brieflink pmc_para_cit" id="crb--__p10" name="crb--__p10" rid="__p10" style="position: absolute; visibility: visible; width: 370px; top: 1636px;">
<div class="portlet_head"></div>
<div class="portlet_content" id="ui-portlet_content-65"><ul><li class="two_line" reference_id="b16">
<a href="http://www.ncbi.nlm.nih.gov/pubmed/10709776/" ref="reftype=pubmed&amp;article-id=1884190&amp;issue-id=144659&amp;journal-id=279&amp;FROM=Article|CitedRefBlock&amp;TO=Entrez|Pubmed|Record&amp;rendering-type=normal"><span class="invert">Review</span> Effects of the antifungal agents on oxidative drug metabolism: clinical relevance.</a><span class="one_line_source">[Clin Pharmacokinet.  2000]</span><div class="alt-note">
<div class="authors">Venkatakrishnan K, von Moltke LL, Greenblatt DJ</div>
<div class="citation">Clin Pharmacokinet. 2000 Feb; 38(2):111-80.</div>
</div>
</li></ul></div>
</div>
<div class="portlet brieflink pmc_para_cit" id="crb--__p17" name="crb--__p17" rid="__p17" style="position: absolute; visibility: visible; width: 370px; top: 2676px;">
<div class="portlet_head"></div>
<div class="portlet_content" id="ui-portlet_content-66"><ul><li class="two_line" reference_id="b19">
<a href="http://www.ncbi.nlm.nih.gov/pubmed/12007766/" ref="reftype=pubmed&amp;article-id=1884190&amp;issue-id=144659&amp;journal-id=279&amp;FROM=Article|CitedRefBlock&amp;TO=Entrez|Pubmed|Record&amp;rendering-type=normal">Quantification of rosuvastatin in human plasma by automated solid-phase extraction using tandem mass spectrometric detection.</a><span class="one_line_source">[J Chromatogr B Analyt Technol Biomed Life Sci.  2002]</span><div class="alt-note">
<div class="authors">Hull CK, Penman AD, Smith CK, Martin PD</div>
<div class="citation">J Chromatogr B Analyt Technol Biomed Life Sci. 2002 Jun 5; 772(2):219-28.</div>
</div>
</li></ul></div>
</div>
<div class="portlet brieflink pmc_para_cit" id="crb--__p24" name="crb--__p24" rid="__p24" style="position: absolute; visibility: visible; width: 370px; top: 4080px;">
<div class="portlet_head"></div>
<div class="portlet_content" id="ui-portlet_content-67"><ul><li class="two_line" reference_id="b20">
<a href="http://www.ncbi.nlm.nih.gov/pubmed/11453898/" ref="reftype=pubmed&amp;article-id=1884190&amp;issue-id=144659&amp;journal-id=279&amp;FROM=Article|CitedRefBlock&amp;TO=Entrez|Pubmed|Record&amp;rendering-type=normal"><span class="invert">Review</span> Optimizing drug development: strategies to assess drug metabolism/transporter interaction potential--towards a consensus.</a><span class="one_line_source">[Br J Clin Pharmacol.  2001]</span><div class="alt-note">
<div class="authors">Tucker GT, Houston JB, Huang SM</div>
<div class="citation">Br J Clin Pharmacol. 2001 Jul; 52(1):107-17.</div>
</div>
</li></ul></div>
</div>
<div class="portlet brieflink pmc_para_cit" id="crb--__p32" name="crb--__p32" rid="__p32" style="position: absolute; visibility: visible; width: 370px; top: 5457px;">
<div class="portlet_head"></div>
<div class="portlet_content" id="ui-portlet_content-68"><ul>
<li class="two_line" reference_id="b6">
<a href="http://www.ncbi.nlm.nih.gov/pubmed/9321523/" ref="reftype=pubmed&amp;article-id=1884190&amp;issue-id=144659&amp;journal-id=279&amp;FROM=Article|CitedRefBlock&amp;TO=Entrez|Pubmed|Record&amp;rendering-type=normal">In vitro metabolism of simvastatin in humans [SBT]identification of metabolizing enzymes and effect of the drug on hepatic P450s.</a><span class="one_line_source">[Drug Metab Dispos.  1997]</span><div class="alt-note">
<div class="authors">Prueksaritanont T, Gorham LM, Ma B, Liu L, Yu X, Zhao JJ, Slaughter DE, Arison BH, Vyas KP</div>
<div class="citation">Drug Metab Dispos. 1997 Oct; 25(10):1191-9.</div>
</div>
</li>
<li class="two_line" reference_id="b7">
<a href="http://www.ncbi.nlm.nih.gov/pubmed/9929499/" ref="reftype=pubmed&amp;article-id=1884190&amp;issue-id=144659&amp;journal-id=279&amp;FROM=Article|CitedRefBlock&amp;TO=Entrez|Pubmed|Record&amp;rendering-type=normal">Comparison of cytochrome P-450-dependent metabolism and drug interactions of the 3-hydroxy-3-methylglutaryl-CoA reductase inhibitors lovastatin and pravastatin in the liver.</a><span class="one_line_source">[Drug Metab Dispos.  1999]</span><div class="alt-note">
<div class="authors">Jacobsen W, Kirchner G, Hallensleben K, Mancinelli L, Deters M, Hackbarth I, Benet LZ, Sewing KF, Christians U</div>
<div class="citation">Drug Metab Dispos. 1999 Feb; 27(2):173-9.</div>
</div>
</li>
<li class="two_line" reference_id="b8" style="display: none;">
<a href="http://www.ncbi.nlm.nih.gov/pubmed/10234598/" ref="reftype=pubmed&amp;article-id=1884190&amp;issue-id=144659&amp;journal-id=279&amp;FROM=Article|CitedRefBlock&amp;TO=Entrez|Pubmed|Record&amp;rendering-type=normal">Erythromycin coadministration increases plasma atorvastatin concentrations.</a><span class="one_line_source">[J Clin Pharmacol.  1999]</span><div class="alt-note">
<div class="authors">Siedlik PH, Olson SC, Yang BB, Stern RH</div>
<div class="citation">J Clin Pharmacol. 1999 May; 39(5):501-4.</div>
</div>
</li>
<li class="two_line" reference_id="b14" style="display: none;">
<a href="http://www.ncbi.nlm.nih.gov/pubmed/8689812/" ref="reftype=pubmed&amp;article-id=1884190&amp;issue-id=144659&amp;journal-id=279&amp;FROM=Article|CitedRefBlock&amp;TO=Entrez|Pubmed|Record&amp;rendering-type=normal">Itraconazole drastically increases plasma concentrations of lovastatin and lovastatin acid.</a><span class="one_line_source">[Clin Pharmacol Ther.  1996]</span><div class="alt-note">
<div class="authors">Neuvonen PJ, Jalava KM</div>
<div class="citation">Clin Pharmacol Ther. 1996 Jul; 60(1):54-61.</div>
</div>
</li>
<li class="two_line" reference_id="b12" style="display: none;">
<a href="http://www.ncbi.nlm.nih.gov/pubmed/9542477/" ref="reftype=pubmed&amp;article-id=1884190&amp;issue-id=144659&amp;journal-id=279&amp;FROM=Article|CitedRefBlock&amp;TO=Entrez|Pubmed|Record&amp;rendering-type=normal">Simvastatin but not pravastatin is very susceptible to interaction with the CYP3A4 inhibitor itraconazole.</a><span class="one_line_source">[Clin Pharmacol Ther.  1998]</span><div class="alt-note">
<div class="authors">Neuvonen PJ, Kantola T, Kivistö KT</div>
<div class="citation">Clin Pharmacol Ther. 1998 Mar; 63(3):332-41.</div>
</div>
</li>
</ul><a href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC1884190/" class="seemore">See more ...</a></div>
</div>
<div class="portlet brieflink pmc_para_cit" id="crb--__p34" name="crb--__p34" rid="__p34" style="position: absolute; visibility: visible; width: 370px; top: 5731px;">
<div class="portlet_head"></div>
<div class="portlet_content" id="ui-portlet_content-69"><ul><li class="two_line" reference_id="b10">
<a href="http://www.ncbi.nlm.nih.gov/pubmed/9695720/" ref="reftype=pubmed&amp;article-id=1884190&amp;issue-id=144659&amp;journal-id=279&amp;FROM=Article|CitedRefBlock&amp;TO=Entrez|Pubmed|Record&amp;rendering-type=normal">Effect of itraconazole on the pharmacokinetics of atorvastatin.</a><span class="one_line_source">[Clin Pharmacol Ther.  1998]</span><div class="alt-note">
<div class="authors">Kantola T, Kivistö KT, Neuvonen PJ</div>
<div class="citation">Clin Pharmacol Ther. 1998 Jul; 64(1):58-65.</div>
</div>
</li></ul></div>
</div>
<div class="portlet brieflink pmc_para_cit" id="crb--__p35" name="crb--__p35" rid="__p35" style="position: absolute; visibility: visible; width: 370px; top: 5910px;">
<div class="portlet_head"></div>
<div class="portlet_content" id="ui-portlet_content-70"><ul>
<li class="two_line" reference_id="b16">
<a href="http://www.ncbi.nlm.nih.gov/pubmed/10709776/" ref="reftype=pubmed&amp;article-id=1884190&amp;issue-id=144659&amp;journal-id=279&amp;FROM=Article|CitedRefBlock&amp;TO=Entrez|Pubmed|Record&amp;rendering-type=normal"><span class="invert">Review</span> Effects of the antifungal agents on oxidative drug metabolism: clinical relevance.</a><span class="one_line_source">[Clin Pharmacokinet.  2000]</span><div class="alt-note">
<div class="authors">Venkatakrishnan K, von Moltke LL, Greenblatt DJ</div>
<div class="citation">Clin Pharmacokinet. 2000 Feb; 38(2):111-80.</div>
</div>
</li>
<li class="two_line" reference_id="b21">
<a href="http://www.ncbi.nlm.nih.gov/pubmed/12463730/" ref="reftype=pubmed&amp;article-id=1884190&amp;issue-id=144659&amp;journal-id=279&amp;FROM=Article|CitedRefBlock&amp;TO=Entrez|Pubmed|Record&amp;rendering-type=normal">No effect of rosuvastatin on the pharmacokinetics of digoxin in healthy volunteers.</a><span class="one_line_source">[J Clin Pharmacol.  2002]</span><div class="alt-note">
<div class="authors">Martin PD, Kemp J, Dane AL, Warwick MJ, Schneck DW</div>
<div class="citation">J Clin Pharmacol. 2002 Dec; 42(12):1352-7.</div>
</div>
</li>
</ul></div>
</div>
</div>   
    </div>
                
        <!-- Custom content below discovery portlets -->
        <div class="col7">
            
        </div>
    </div>
</div>

<!-- Custom content after all -->
<div class="col8">
    
</div>
<div class="col9">
    
</div>

<script src="./PMC1884190_files/jquery.scrollTo-1.4.2.js"></script>
<script>
    (function($){
        $('.skiplink').each(function(i, item){
            var href = $($(item).attr('href'));
            href.attr('tabindex', '-1').addClass('skiptarget'); // ensure the target can receive focus
            $(item).on('click', function(event){
                event.preventDefault();
                $.scrollTo(href, 0, {
                    onAfter: function(){
                        href.focus();
                    }
                });
            });
        });
    })(jQuery);
</script>



<div id="body-link-poppers"><div id="body-link-popper-b1" class="body-link-popper ui-helper-reset ui-ncbipopper-wrapper ui-ncbipopper-basic" style="display: none; width: 30em; top: -100px; left: -100px;" aria-live="assertive" aria-hidden="true">Effect of rosuvastatin on low-density lipoprotein cholesterol in patients with hypercholesterolemia.<div class="authors">Olsson AG, Pears J, McKellar J, Mizan J, Raza A</div><div class="citation">Am J Cardiol. 2001 Sep 1; 88(5):504-8.</div><p>[<a href="http://www.ncbi.nlm.nih.gov/pubmed/11524058/">PubMed</a>] [<a href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC1884190/#b1">Ref list</a>]</p></div><div id="body-link-popper-b2" class="body-link-popper ui-helper-reset ui-ncbipopper-wrapper ui-ncbipopper-basic" style="display: none; width: 30em; top: -100px; left: -100px;" aria-live="assertive" aria-hidden="true">No effect of age or gender on the pharmacokinetics of rosuvastatin: a new HMG-CoA reductase inhibitor.<div class="authors">Martin PD, Dane AL, Nwose OM, Schneck DW, Warwick MJ</div><div class="citation">J Clin Pharmacol. 2002 Oct; 42(10):1116-21.</div><p>[<a href="http://www.ncbi.nlm.nih.gov/pubmed/12362926/">PubMed</a>] [<a href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC1884190/#b2">Ref list</a>]</p></div><div id="body-link-popper-b3" class="body-link-popper ui-helper-reset ui-ncbipopper-wrapper ui-ncbipopper-basic" style="display: none; width: 30em; top: -100px; left: -100px;" aria-live="assertive" aria-hidden="true">3. <span class="citation">Martin PD, Dane AL, Schneck DW, Warwick MJ. Disposition of new HMG-CoA reductase inhibitor ZD4522 following dosing in healthy subjects. <span><span class="ref-journal">J Clin Pharmacol. </span>2000;<span class="ref-vol">40</span>:1056.</span> [Abstr. 48]</span> [<a href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC1884190/#b3">Ref list</a>]</div><div id="body-link-popper-b4" class="body-link-popper ui-helper-reset ui-ncbipopper-wrapper ui-ncbipopper-basic" style="display: none; width: 30em; top: -100px; left: -100px;" aria-live="assertive" aria-hidden="true">4. <span class="citation">McCormick AD, McKillop D, Butters CJ, et al.  ZD4522—an HMG-CoA reductase inhibitor free of metabolically mediated drug interactions: metabolic studies in human <em>in vitro</em> systems. <span><span class="ref-journal">J Clin Pharmacol. </span>2000;<span class="ref-vol">40</span>:1055.</span> [Abstr. 46]</span> [<a href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC1884190/#b4">Ref list</a>]</div><div id="body-link-popper-b5" class="body-link-popper ui-helper-reset ui-ncbipopper-wrapper ui-ncbipopper-basic" style="display: none; width: 30em; top: -100px; left: -100px;" aria-live="assertive" aria-hidden="true">5. <span class="citation">Michniewicz BM, Black AE, Sinz MW, Woolf TF. <em>In vitro</em> and <em>in vivo</em> metabolism of atorvastatin (CI-981) l. <span><span class="ref-journal">ISSX Proc. </span>1994;<span class="ref-vol">6</span>:93.</span></span> [<a href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC1884190/#b5">Ref list</a>]</div><div id="body-link-popper-b6" class="body-link-popper ui-helper-reset ui-ncbipopper-wrapper ui-ncbipopper-basic" style="display: none; width: 30em; top: -100px; left: -100px;" aria-live="assertive" aria-hidden="true">In vitro metabolism of simvastatin in humans [SBT]identification of metabolizing enzymes and effect of the drug on hepatic P450s.<div class="authors">Prueksaritanont T, Gorham LM, Ma B, Liu L, Yu X, Zhao JJ, Slaughter DE, Arison BH, Vyas KP</div><div class="citation">Drug Metab Dispos. 1997 Oct; 25(10):1191-9.</div><p>[<a href="http://www.ncbi.nlm.nih.gov/pubmed/9321523/">PubMed</a>] [<a href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC1884190/#b6">Ref list</a>]</p></div><div id="body-link-popper-b7" class="body-link-popper ui-helper-reset ui-ncbipopper-wrapper ui-ncbipopper-basic" style="display: none; width: 30em; top: -100px; left: -100px;" aria-live="assertive" aria-hidden="true">Comparison of cytochrome P-450-dependent metabolism and drug interactions of the 3-hydroxy-3-methylglutaryl-CoA reductase inhibitors lovastatin and pravastatin in the liver.<div class="authors">Jacobsen W, Kirchner G, Hallensleben K, Mancinelli L, Deters M, Hackbarth I, Benet LZ, Sewing KF, Christians U</div><div class="citation">Drug Metab Dispos. 1999 Feb; 27(2):173-9.</div><p>[<a href="http://www.ncbi.nlm.nih.gov/pubmed/9929499/">PubMed</a>] [<a href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC1884190/#b7">Ref list</a>]</p></div><div id="body-link-popper-b8" class="body-link-popper ui-helper-reset ui-ncbipopper-wrapper ui-ncbipopper-basic" style="display: none; width: 30em; top: -100px; left: -100px;" aria-live="assertive" aria-hidden="true">Erythromycin coadministration increases plasma atorvastatin concentrations.<div class="authors">Siedlik PH, Olson SC, Yang BB, Stern RH</div><div class="citation">J Clin Pharmacol. 1999 May; 39(5):501-4.</div><p>[<a href="http://www.ncbi.nlm.nih.gov/pubmed/10234598/">PubMed</a>] [<a href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC1884190/#b8">Ref list</a>]</p></div><div id="body-link-popper-b10" class="body-link-popper ui-helper-reset ui-ncbipopper-wrapper ui-ncbipopper-basic" style="display: none; width: 30em; top: -100px; left: -100px;" aria-live="assertive" aria-hidden="true">Effect of itraconazole on the pharmacokinetics of atorvastatin.<div class="authors">Kantola T, Kivistö KT, Neuvonen PJ</div><div class="citation">Clin Pharmacol Ther. 1998 Jul; 64(1):58-65.</div><p>[<a href="http://www.ncbi.nlm.nih.gov/pubmed/9695720/">PubMed</a>] [<a href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC1884190/#b10">Ref list</a>]</p></div><div id="body-link-popper-b11" class="body-link-popper ui-helper-reset ui-ncbipopper-wrapper ui-ncbipopper-basic" style="display: none; width: 30em; top: -100px; left: -100px;" aria-live="assertive" aria-hidden="true">Erythromycin and verapamil considerably increase serum simvastatin and simvastatin acid concentrations.<div class="authors">Kantola T, Kivistö KT, Neuvonen PJ</div><div class="citation">Clin Pharmacol Ther. 1998 Aug; 64(2):177-82.</div><p>[<a href="http://www.ncbi.nlm.nih.gov/pubmed/9728898/">PubMed</a>] [<a href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC1884190/#b11">Ref list</a>]</p></div><div id="body-link-popper-b12" class="body-link-popper ui-helper-reset ui-ncbipopper-wrapper ui-ncbipopper-basic" style="display: none; width: 30em; top: -100px; left: -100px;" aria-live="assertive" aria-hidden="true">Simvastatin but not pravastatin is very susceptible to interaction with the CYP3A4 inhibitor itraconazole.<div class="authors">Neuvonen PJ, Kantola T, Kivistö KT</div><div class="citation">Clin Pharmacol Ther. 1998 Mar; 63(3):332-41.</div><p>[<a href="http://www.ncbi.nlm.nih.gov/pubmed/9542477/">PubMed</a>] [<a href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC1884190/#b12">Ref list</a>]</p></div><div id="body-link-popper-b13" class="body-link-popper ui-helper-reset ui-ncbipopper-wrapper ui-ncbipopper-basic" style="display: none; width: 30em; top: -100px; left: -100px;" aria-live="assertive" aria-hidden="true">Different effects of itraconazole on the pharmacokinetics of fluvastatin and lovastatin.<div class="authors">Kivistö KT, Kantola T, Neuvonen PJ</div><div class="citation">Br J Clin Pharmacol. 1998 Jul; 46(1):49-53.</div><p>[<a href="http://www.ncbi.nlm.nih.gov/pubmed/9690949/">PubMed</a>] [<a href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC1884190/#b13">Ref list</a>]</p></div><div id="body-link-popper-b14" class="body-link-popper ui-helper-reset ui-ncbipopper-wrapper ui-ncbipopper-basic" style="display: none; width: 30em; top: -100px; left: -100px;" aria-live="assertive" aria-hidden="true">Itraconazole drastically increases plasma concentrations of lovastatin and lovastatin acid.<div class="authors">Neuvonen PJ, Jalava KM</div><div class="citation">Clin Pharmacol Ther. 1996 Jul; 60(1):54-61.</div><p>[<a href="http://www.ncbi.nlm.nih.gov/pubmed/8689812/">PubMed</a>] [<a href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC1884190/#b14">Ref list</a>]</p></div><div id="body-link-popper-b15" class="body-link-popper ui-helper-reset ui-ncbipopper-wrapper ui-ncbipopper-basic" style="display: none; width: 30em; top: -100px; left: -100px;" aria-live="assertive" aria-hidden="true"><span class="invert">Review</span> Systemic antifungal agents. Drug interactions of clinical significance.<div class="authors">Albengres E, Le Louët H, Tillement JP</div><div class="citation">Drug Saf. 1998 Feb; 18(2):83-97.</div><p>[<a href="http://www.ncbi.nlm.nih.gov/pubmed/9512916/">PubMed</a>] [<a href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC1884190/#b15">Ref list</a>]</p></div><div id="body-link-popper-b16" class="body-link-popper ui-helper-reset ui-ncbipopper-wrapper ui-ncbipopper-basic" style="display: none; width: 30em; top: -100px; left: -100px;" aria-live="assertive" aria-hidden="true"><span class="invert">Review</span> Effects of the antifungal agents on oxidative drug metabolism: clinical relevance.<div class="authors">Venkatakrishnan K, von Moltke LL, Greenblatt DJ</div><div class="citation">Clin Pharmacokinet. 2000 Feb; 38(2):111-80.</div><p>[<a href="http://www.ncbi.nlm.nih.gov/pubmed/10709776/">PubMed</a>] [<a href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC1884190/#b16">Ref list</a>]</p></div><div id="body-link-popper-b17" class="body-link-popper ui-helper-reset ui-ncbipopper-wrapper ui-ncbipopper-basic" style="display: none; width: 30em; top: -100px; left: -100px;" aria-live="assertive" aria-hidden="true">17. <span class="citation">Nezasa K, Takeuchi M, Yukawa T, et al.  Tissue specific distribution of S-4522, a novel 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitor, to the liver in rats l. <span><span class="ref-journal">Xenobiotic Metab Dispos. </span>1998;<span class="ref-vol">13</span>(Suppl):S226.</span></span> [<a href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC1884190/#b17">Ref list</a>]</div><div id="body-link-popper-b18" class="body-link-popper ui-helper-reset ui-ncbipopper-wrapper ui-ncbipopper-basic" style="display: none; width: 30em; top: -100px; left: -100px;" aria-live="assertive" aria-hidden="true">18. <span class="citation">Brown CDA, Windass A, Bleasby K, Lauffart B. Rosuvastatin is a high affinity substrate of hepatic organic anion transporter OATP-C l. <span><span class="ref-journal">Atheroscler Suppl. </span>2001;<span class="ref-vol">2</span>:90.</span> (P174)</span> [<a href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC1884190/#b18">Ref list</a>]</div><div id="body-link-popper-b19" class="body-link-popper ui-helper-reset ui-ncbipopper-wrapper ui-ncbipopper-basic" style="display: none; width: 30em; top: -100px; left: -100px;" aria-live="assertive" aria-hidden="true">Quantification of rosuvastatin in human plasma by automated solid-phase extraction using tandem mass spectrometric detection.<div class="authors">Hull CK, Penman AD, Smith CK, Martin PD</div><div class="citation">J Chromatogr B Analyt Technol Biomed Life Sci. 2002 Jun 5; 772(2):219-28.</div><p>[<a href="http://www.ncbi.nlm.nih.gov/pubmed/12007766/">PubMed</a>] [<a href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC1884190/#b19">Ref list</a>]</p></div><div id="body-link-popper-b20" class="body-link-popper ui-helper-reset ui-ncbipopper-wrapper ui-ncbipopper-basic" style="display: none; width: 30em; top: -100px; left: -100px;" aria-live="assertive" aria-hidden="true"><span class="invert">Review</span> Optimizing drug development: strategies to assess drug metabolism/transporter interaction potential--towards a consensus.<div class="authors">Tucker GT, Houston JB, Huang SM</div><div class="citation">Br J Clin Pharmacol. 2001 Jul; 52(1):107-17.</div><p>[<a href="http://www.ncbi.nlm.nih.gov/pubmed/11453898/">PubMed</a>] [<a href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC1884190/#b20">Ref list</a>]</p></div><div id="body-link-popper-b21" class="body-link-popper ui-helper-reset ui-ncbipopper-wrapper ui-ncbipopper-basic" style="display: none; width: 30em; top: -100px; left: -100px;" aria-live="assertive" aria-hidden="true">No effect of rosuvastatin on the pharmacokinetics of digoxin in healthy volunteers.<div class="authors">Martin PD, Kemp J, Dane AL, Warwick MJ, Schneck DW</div><div class="citation">J Clin Pharmacol. 2002 Dec; 42(12):1352-7.</div><p>[<a href="http://www.ncbi.nlm.nih.gov/pubmed/12463730/">PubMed</a>] [<a href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC1884190/#b21">Ref list</a>]</p></div></div>
                        </div>
                        <div class="bottom">
                            
                            <div id="NCBIFooter_dynamic">
    <div class="breadcrumbs">You are here: 
            <span id="breadcrumb_text"><a href="http://www.ncbi.nlm.nih.gov/guide/">NCBI</a> &gt; <a href="http://www.ncbi.nlm.nih.gov/guide/literature/">Literature</a> &gt; <a href="http://www.ncbi.nlm.nih.gov/pmc/">PubMed Central (PMC)</a></span></div>
    <a id="help-desk-link" class="help_desk jig-ncbihelpwindow" target="_blank" href="http://www.ncbi.nlm.nih.gov/sites/ehelp?&amp;Ncbi_App=pmc&amp;Db=pmc&amp;Page=literature&amp;Snapshot=/projects/PMC/PMCViewer@4.35&amp;Time=2016-06-23T14:13:07-04:00&amp;Host=ptpmc101">Write to the Help Desk</a>
    
</div>

                            <div class="footer" id="footer">
    
    <div class="subfooter"> </div><script type="text/javascript" src="./PMC1884190_files/preloaderWidget.js"> </script>
    <div id="external-disclaimer" class="offscreen_noflow">
        External link. Please review our <a href="http://www.nlm.nih.gov/privacy.html">privacy policy</a>.
    </div>    
    <div id="ncbifooter" class="contact_info">      
        <div id="footer-contents-right">
            <div id="nlm_thumb_logo">
                <a href="http://www.nlm.nih.gov/" title="NLM">NLM</a>
            </div>
            <div id="nih_thumb_logo">
                <a href="http://www.nih.gov/" title="NIH">NIH</a>
            </div>
            <div id="hhs_thumb_logo">
                <a href="http://www.dhhs.gov/" title="DHHS">DHHS</a>
            </div>
            <div id="usagov_thumb_logo">
                <a href="http://www.usa.gov/" title="USA.gov">USA.gov</a>
            </div>         
        </div>
        
        <div id="footer-contents-left">
            
            <a href="http://www.ncbi.nlm.nih.gov/About/disclaimer.html">Copyright</a> | <a href="http://www.ncbi.nlm.nih.gov/About/disclaimer.html#disclaimer">Disclaimer</a> |
            <a href="http://www.nlm.nih.gov/privacy.html" class="newdomain">Privacy</a> | 
            <a href="http://www.ncbi.nlm.nih.gov/guide/browsers/">Browsers</a> | <a href="http://www.nlm.nih.gov/accessibility.html">Accessibility</a> | <a href="http://www.ncbi.nlm.nih.gov/About/glance/contact_info.html">Contact</a>
            <p class="address vcard">
                <span class="url">
                    <a class="fn url newdomain" href="http://www.ncbi.nlm.nih.gov/">National Center for
                        Biotechnology Information</a>,
                </span> <span class="org url"><a href="http://www.nlm.nih.gov/">U.S. National Library of Medicine</a></span>
                <span class="adr">
                    <span class="street-address">8600 Rockville Pike</span>, <span class="locality">Bethesda</span>
                    <span class="region">MD</span>, <span class="postal-code">20894</span>
                    <span class="country-name">USA</span>
                </span>
            </p>
        </div>
    </div>
    <script type="text/javascript" src="./PMC1884190_files/InstrumentPageStarterJS.js"> </script>    
    <script type="text/javascript" src="./PMC1884190_files/hfjs2.js"> </script>
</div>
                        </div>
                    </div>
                    <!--/.page-->
                </div>
                <!--/.wrap-->
            </div><!-- /.twelve_col -->
        <div style="display: none; top: -100px; left: -100px;" aria-live="assertive" aria-hidden="true" class="ui-helper-reset ui-ncbipopper-wrapper ui-ncbipopper-basic">External link. Please review our <a href="http://www.nlm.nih.gov/privacy.html">privacy policy</a>.</div><div class="ui-ncbiautocomplete-holder shadow ui-ncbiautocomplete-holder-clearfix" aria-live="assertive" style="display: none; top: 63.5938px; left: 408.188px; width: 670px; z-index: 1001;"><ul class="ui-ncbiautocomplete-options" role="listbox" aria-activedescendant="term"></ul><div class="ui-ncbiautocomplete-actions shadow" style="display: none;"><a class="ui-ncbiautocomplete-link-pref" style="display: none;">Preferences</a><a href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC1884190/#" class="ui-ncbiautocomplete-link-off ui-ncbiautocomplete-link-pref-right" style="display: none;">Turn off</a></div></div></div>
        <!-- /.grid -->

        <span class="PAFAppResources"></span>
        
        <!-- BESelector tab -->
        
        
        
        <noscript>&lt;img alt="statistics" src="/stat?jsdisabled=true&amp;amp;ncbi_db=pmc&amp;amp;ncbi_pdid=article&amp;amp;ncbi_acc=&amp;amp;ncbi_domain=brjclinpharm&amp;amp;ncbi_report=record&amp;amp;ncbi_type=fulltext&amp;amp;ncbi_objectid=&amp;amp;ncbi_pcid=/articles/PMC1884190/&amp;amp;ncbi_app=pmc" /&gt;</noscript>
        
        
        <!-- usually for JS scripts at page bottom -->
        <!--<component id="PageFixtures" label="styles"></component>-->
    

<!-- F4FC7E8376854741_0014SID /projects/PMC/PMCViewer@4.35 ptpmc101 v4.1.r480124 Mon, Sep 28 2015 02:46:19 -->

<script type="text/javascript" src="./PMC1884190_files/4065628.js" snapshot="pmc"></script>
<div class="ui-dialog ui-widget ui-widget-content ui-corner-all ui-front" tabindex="-1" role="dialog" aria-describedby="epubDialog" aria-labelledby="ui-id-1" style="display: none;"><div class="ui-dialog-titlebar ui-widget-header ui-corner-all ui-helper-clearfix"><span id="ui-id-1" class="ui-dialog-title">Making articles easier to read in PMC</span><button type="button" class="ui-button ui-widget ui-state-default ui-corner-all ui-button-icon-only ui-dialog-titlebar-close" role="button" title="Close"><span class="ui-button-icon-primary ui-icon ui-icon-closethick"></span><span class="ui-button-text">Close</span></button></div><div id="epubDialog" style="display: block;" class="ui-dialog-content ui-widget-content">  <p>We are experimenting with display styles that make it easier to read articles     in PMC.     Our first effort uses eBook readers, which have several "ease of reading"     features already built in.</p>  <p>These PMC articles are best viewed in the <em>iBooks     reader</em>. You may notice problems with the display of certain parts of an article     in other eReaders.</p>  <div class="ui-dialog-buttonpane ui-widget-content ui-helper-clearfix"><button id="cancelEpub" class="ui-state-default ui-corner-all">Cancel</button><button id="downloadEpub" style="float: left" class="ui-state-default ui-corner-all">Download article</button></div>          </div></div><ul class="print-log"><li></li></ul></body></html>